US Pat. No. 11,026,368

STEERING CONTROL SYSTEM FOR HARVESTER AND METHODS OF USING THE SAME

CNH INDUSTRIAL AMERICA LL...

20. A harvester, comprising:a frame;
at least one front axle comprising first and second front wheels pivotally mounted to the front axle;
at least one rear axle comprising first and second casters pivotally mounted to the rear axle; and
a steering control system comprising:
a first cylinder coupled to the rear axle at one end and rigidly coupled to an upright shaft of the first caster at an opposing end;
a sensor associated with the first cylinder and in communication with a controller, the sensor detecting a position of the first cylinder; and
a second cylinder coupled to the rear axle at one end and an upright shaft of the second caster at an opposing end;
wherein in a road operation mode, the first cylinder is actuated by the controller to extend or retract to control steering of the first caster, and the sensor transmits data to the controller regarding the detected position of the first cylinder; and
wherein the second cylinder is free of sensing and is hydraulically coupled to the first cylinder to move in an equal and opposite direction of the first cylinder to control steering of the second caster.

US Pat. No. 11,026,367

GARDEN TOOLS

Suzhou Cleva Precision Ma...

1. A garden tool, comprising:a power assembly including an internal combustion engine having a starter motor;
a battery pack for supplying power to the starter motor;
a connecting rod assembly having two ends;
a working head assembly, the working head assembly and the power assembly being respectively arranged at the two ends of the connecting rod assembly;
a handle assembly including two handles, one of the handles being on a left side of the connecting rod assembly and another of the handles being on a right side of the connecting rod assembly, at least one of the handles including a grip portion and a battery pack mounting portion, the battery pack being detachably connected to the battery pack mounting portion;
an accommodating chamber defined by the battery pack mounting portion, the battery pack being mounted on the battery pack mounting portion by being at least partially received in the accommodating chamber, the accommodating chamber defining an opening facing forward; and
a circuit board disposed adjacent to the accommodating chamber, the circuit board including a substrate and an electrode holder disposed on a side of the substrate facing the accommodating chamber, the electrode holder including a clamping pin extending into the accommodating chamber.

US Pat. No. 11,026,366

POWER EQUIPMENT

HONDA MOTOR CO., LTD., T...

1. Walk-behind power equipment, comprising:a main body provided with at least one front wheel and a pair of left and right rear wheels;
a work unit provided on the main body;
a pair of left and right travel motors provided for the respective rear wheels;
a handle connected to the main body and extending rearward and upward;
a tilt angle detector that detects a tilt angle of the main body;
a yaw rate detector that detects a yaw rate generated on the main body; and
a control unit that drive-controls the travel motors,
wherein the control unit determines whether the main body is in a rearward tilted state based on the tilt angle, and if it is determined that the main body is not in the rearward tilted state, the control unit performs straight-line travel control to set a rotational speed difference between the left and right travel motors to reduce the yaw rate, and if it is determined that the main body is in the rearward tilted state, the control unit does not perform the straight-line travel control.

US Pat. No. 11,026,365

DISTRIBUTOR DEVICE FOR SOLIDS CONTAINING LIQUIDS

1. A distributor device for solids-laden fluids comprising:a distributor housing comprising a housing underside and a housing topside opposite the housing underside which define an interior space that is subdivided into a fluid space into which an inlet port opens and a ventilation space separate therefrom into which a ventilation port opens;
a plurality of outlet ports;
the inlet port in the distributor housing, the inlet port opening into an inlet passage which extends from the housing topside into the fluid space;
the ventilation port disposed in the housing topside of the distributor housing, the ventilation port being formed by an annular passage around the inlet passage into which the inlet port opens; and
a rotor which is movable relative to the distributor housing and disposed inside the distributor housing, and which connects each of the plurality of outlet ports in fluid communication with the fluid space and with the ventilation space in alternating succession;
wherein the relative movement of the rotor connects an outlet port of the plurality of outlet ports alternately with the fluid space and the ventilation space.

US Pat. No. 11,026,364

AGRICULTURAL METERING SYSTEM HAVING MULTIPLE SETS OF METER ROLLERS

CNH Industrial Canada, Lt...

1. An agricultural metering system, comprising:a plurality of independently controllable sets of meter rollers, wherein each set of meter rollers of the plurality of independently controllable sets of meter rollers comprises at least one meter roller and is configured to rotate about a respective rotational axis, and the rotational axes are generally parallel to one another and not aligned with one another;
a plurality of meter boxes configured to receive agricultural product from a compartment of a storage tank, wherein each set of meter rollers of the plurality of independently controllable sets of meter rollers is disposed within a respective meter box of the plurality of meter boxes, and each set of meter rollers of the plurality of independently controllable sets of meter rollers is configured to meter the agricultural product from the compartment of the storage tank; and
a plurality of distribution lines, wherein each distribution line of the plurality of distribution lines is disposed downstream from a respective set of meter rollers of the plurality of independently controllable sets of meter rollers and is configured to receive the agricultural product that is output from the respective set of meter rollers.

US Pat. No. 11,026,363

ROW UNIT WITH INTEGRATED PRESSURE SOURCE

Kinze Manufacturing, Inc....

1. A seed meter for use on a row unit of an agricultural implement, comprising:a housing comprising a seed disc side and a vacuum side;
a seed disc rotatably positioned within the housing and including a plurality of seed apertures; and
an integrated, electric fluid pressure source positioned at the vacuum side of the housing and configured to create a pressure differential at the seed apertures of the seed disc to temporarily adhere a seed thereat.

US Pat. No. 11,026,362

SYSTEM AND METHOD FOR TREATING INDIVIDUAL SEEDS WITH LIQUID CHEMICALS DURING THE PLANTING PROCESS

AMVAC CHEMICAL CORPORATIO...

1. A system for dispensing liquid agricultural products with seed, comprising:a control system for receiving at least one control input;
a seed transport mechanism affixed to a seed planter row unit, configured to dispense seed;
an agricultural product supply system configured to dispense agricultural products in response to an output signal from said control system;
a seed brush assembly, comprising:
a) a brush housing structure for receiving seed from the seed transport mechanism; and,
b) a brush having bristles positioned within said brush housing structure;
wherein said agricultural product supply system is configured to dispense said liquid agricultural products onto the bristles,
wherein said bristles are positioned and configured to minimize the resistance associated with the passage of seed past the wetted bristles, and,
wherein said liquid agricultural product is transferred from the brushes onto the seed when the seed is dispensed prior to the seed hitting the ground.
US Pat. No. 11,026,991

COMPOSITIONS AND METHODS OF USE THEREOF TO PROMOTE MUSCLE GROWTH AND FUNCTION

Ingenious Ingredients, LP...

1. A composition for increasing muscle protein synthesis comprising:a. dileucine, and
b. leucine
wherein the dileucine is present in an amount of at least about 50% (w/w) of the combined weight of dileucine and leucine.
US Pat. No. 11,028,015

GLASS BALL HAVING SPECIFIC YOUNG'S MODULUS AND COEFFICIENT OF THERMAL EXPANSION

AGC Inc., Chiyoda-ku (JP...

1. A glass ball, having:a density of 2.3 to 3.2 g/cm3;
a Young's modulus of 60 to 150 GPa; and
an average coefficient of thermal expansion at 50 to 350° C. being 40×10?7 to 120×10?7/° C.,
the glass ball being formed of a glass material comprising, as represented by mole percentage based on oxides, 30 to 75 mol % of SiO2, 2 to 30 mol % of Al2O3, and 5 to 25 mol % of R2O, wherein R is at least one kind selected from Li, Na and K, and
the glass ball comprising a compressive stress layer in a surface thereof.
US Pat. No. 11,026,992

COMPOSITIONS AND METHODS FOR PREVENTING AND REDUCING INFLAMMATION AND TREATING DISORDERS ASSOCIATED WITH INFLAMMATION

Vanderbilt University, N...

1. A composition comprising a pharmaceutically acceptable carrier and a cell-penetrating caspase and receptor interacting protein adaptor with death domain (CP-CRADD) in an amount sufficient to reduce or block BCL10 expression or activity, reduce BCL-10-mediated inflammation, and/or treat BCL-10-mediated inflammation with a condition in a subject; wherein the death domain of CP-CRADD is deleted.
US Pat. No. 11,027,249

AZEOTROPE-LIKE COMPOSITIONS OF 1,1,1,2-TETRAFLUOROPROPENE AND 1,1,1,2-TETRAFLUOROETHANE

Honeywell International I...

1. An azeotrope-like composition consisting essentially of from about 43.38 percent by weight to about 65.16 percent by weight of 1,1,1,2-tetrafluoropropene and from about 34.84 percent by weight to about 56.62 percent by weight of 1,1,1,2-tetrafluoroethane to form a non-flammable composition, said composition being azeotropic at least one concentration of the components within said range of component concentrations, said non-flammable composition having a boiling point that is below the boiling point of said 1,1,1,2-tetrafluoropropene and said 1,1,1,2-tetrafluoroethane and that is from about ?29.16° C. to about ?29.92° C. at a pressure of about 14.3 psia.
US Pat. No. 11,026,994

SYNDECAN-2 COMPOSITIONS AND METHODS OF USE

ORBSEN THERAPEUTICS LIMIT...

1. A method of reducing an inflammatory response in a subject, the method comprising contacting a cell of the subject with a composition comprising Syndecan-2 (SDC2) or a fragment of SDC2, wherein the SDC2 or the fragment of SDC2 has an anti-inflammatory effect.
US Pat. No. 11,028,018

EROSION-RESISTANT CERAMIC MATERIAL, POWDER, SLIP AND COMPONENT

1. A powder comprising (in % by weight):aluminum oxide in an amount of from 92.0% to <99.0%; and
spinel in a proportion of 8.0%-1.0%.
US Pat. No. 11,031,093

SYSTEMS AND METHODS FOR IDENTIFYING THERMODYNAMICALLY RELEVANT POLYMER CONFORMATIONS

ZYMEWORKS INC., Vancouve...

1. A method of evaluating an effect that a mutation of a polypeptide of known sequence and structure has on the polypeptide by identifying one or more conformations for the polypeptide upon incorporation of the mutation, wherein the polypeptide comprises a plurality of atoms, and wherein the polypeptide comprises at least one contiguous segment of main chain, the method comprising:at a computer system having one or more processors and memory storing one or more programs to be executed by the one of more processors:
(A) obtaining an initial set of three-dimensional coordinates {x1, . . . , xN} for the polypeptide, wherein each respective xi in {x1, . . . , xN} is a three dimensional coordinate for an atom in the plurality of atoms in said polypeptide;
(B) identifying, in silico, a residue of the polypeptide, and replacing the residue with a different residue, thereby defining a sequence of a mutated polypeptide;
(C) identifying a region of the polypeptide based upon the identity of the replaced residue of the mutated polypeptide, the region comprising a plurality of residues;
(D) altering a side-chain rotamer conformation, with respect to the initial set of three-dimensional coordinates {x1, . . . , xN} of each residue in a subset of residues in the region of the polypeptide, for each respective subset of residues in the region of the polypeptide in a plurality of subsets of residues in the region of the polypeptide, thereby deriving a plurality of mutated polypeptide structures of the region of the polypeptide,
wherein each respective subset of residues in the plurality of subsets of residues in the region of the polypeptide is selected from among all the residues in the region of the polypeptide using a deterministic, randomized or pseudo-randomized algorithm;
(E) generating a plurality of sets of clusters for each respective residue in the region of the polypeptide, using the plurality of mutated polypeptide structures derived in (D), wherein
each respective set of clusters in the plurality of sets of clusters is for
(i) a side chain or a main chain of a respective residue in the region of the polypeptide in which each respective cluster in the respective set of clusters is formed by clustering a conformation of the side chain or main chain of the respective residue in each mutated polypeptide structure in the plurality of mutated polypeptide structures derived in (D) or
(ii) a contiguous segment of the main chain in the at least one contiguous segment of main chain in the region of the polypeptide in which each respective cluster in the respective set of clusters is formed by clustering a structural metric associated with the main chain of the contiguous segment of the main chain in each mutated polypeptide structure in the plurality of mutated polypeptide structures derived in (D);
(F) grouping respective mutated polypeptide structures in the plurality of mutated polypeptide structures into a plurality of subgroups, wherein each mutated polypeptide structure in a subgroup in the plurality of subgroups falls into the same cluster in a threshold number of the sets of clusters in the plurality of sets of clusters; and
(G) determining a free energy estimate or configurational entropy of a plurality of mutated polypeptide structures in each subgroup in the plurality of subgroups, thereby identifying the effect that the mutation of the polypeptide has on the polypeptide in the form of the free energy estimate or the configurational entropy in each subgroup in the plurality of subgroups.
US Pat. No. 11,026,995

USE OF CD24 FOR LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS

ONCOIMMUNE, INC., Wilmin...

1. A method for treating low-density lipoprotein cholesterol (LDL-C)-associated atherosclerosis in a human subject in need thereof, comprising administering to the subject a CD24 protein, wherein the CD24 protein comprises a mature human CD24 polypeptide comprising the sequence set forth in SEQ ID NO: 1 or 2, and wherein the mature human CD24 polypeptide is fused at its C-terminus to a Fc region of a human IgG protein.
US Pat. No. 11,028,019

BORON CARBIDE COMPOSITE

Purdue Research Foundatio...

1. A composite material comprising a sintered product of a mixture comprising 70-95 wt. % of boron carbide (B4C), 2-15 wt. % of tungsten carbide-cobalt (WC—Co), and 3-15 wt. % of yttrium oxide (Y2O3), wherein said boron carbide, tungsten carbide-cobalt (WC—Co), and yttrium oxide are substantially uniformly distributed in the sintered product, wherein the sintered product has a relative density of 90-99%.
US Pat. No. 11,028,275

DEVELOPMENT OF A SOL-GEL ANTICORROSION TREATMENT

SAFRAN, Paris (FR) RBNAN...

1. A treatment process for a metal alloy part comprising the following steps:produce a stock formulation by mixing, in equal molar parts of silicon, an alcoholic solution of hydrolyzed epoxysilane and an alcoholic solution of hydrolyzed aminosilane,
mix the stock formulation with a suspension comprising conductive nanowires in an amount by weight between 0.1% and 10% based on the total weight of the stock formulation to obtain a dilute formulation, and
deposit the dilute formulation on the part to obtain the coating,
wherein the stock formulation further comprises fluorosilane, at a molar concentration between 0.5% and 5% based on the silicon derived from the epoxysilane and from the aminosilane and/or from the nanometric silica, at a molar concentration between 1% and 5% based on the silicon derived from the epoxysilane and from the aminosilane.
US Pat. No. 11,028,531

FLAME RESISTANT AND CHEMICAL PROTECTIVE TEXTILE MATERIAL

1. A treated textile material comprising:(a) a textile substrate having a first surface, the textile substrate comprising a plurality of first yarns and a plurality of second yarns, the plurality of first yarns being disposed in a first direction in the textile substrate, the plurality of second yarns being disposed in a second direction perpendicular to the first direction, the plurality of first yarns and the plurality of second yarns being interwoven, the first yarns and second yarns each comprising about 90 wt. % or more of inherent flame resistant staple fibers, the textile substrate having an areal density of about 150 g/m2 or more and an optical transparency of about 10% or less; and
(b) a finish disposed on the first yarns and the second yarns, the finish comprising a fluorochemical repellent, the fluorochemical repellent being present on the textile material in an amount of about 0.05 grams or more of fluorochemical repellent per gram of the textile substrate,
wherein the treated textile material exhibits an air permeability of about 1,400 l/min or more.
US Pat. No. 11,031,094

PROTEIN STRUCTURE PREDICTION SYSTEM

DNASTAR, INC., Madison, ...

1. A conformational sampling method for predicting the structure of an amino acid sequence, the amino acid sequence comprising a plurality of residues, comprising: a) creating a sequence profile matrix of the amino acid sequence; b) determining an alignment of each respective residue of the amino acid sequence against the sequence profile matrix; c) identifying internal residue contacts for one or more residues in the plurality of residues using the alignment; d) collecting the features of the sequence profile matrix and internal residue contacts for each residue in the plurality of residues into a collected feature matrix; e) aligning the collected feature matrix using one or more threading models with a structural feature database of original templates; f) selecting a plurality of optimally aligned original templates from the aligning e); g) calculating normal modes of motion for each original template in the plurality of optimally aligned original templates; h) perturbing each respective original template in the plurality of optimally aligned original templates, for each pair of calculated normal modes, thereby collectively creating a plurality of synthetic templates; i) scoring the energy difference between each original template and the corresponding synthetic template; j) selecting a subset of synthetic templates from the plurality of synthetic templates based on satisfaction of a predetermined cut-off criterion; k) replacing or supplementing the original templates in the plurality of optimally aligned original templates with the corresponding selected subset of synthetic templates to generate a plurality of modeling templates; l) calculating distance and contact restraints within modeling templates of the plurality of modeling templates; m) performing, with modeling templates in the plurality of modeling templates, Markov Chain Monte Carlo simulations, thereby obtaining simulation results; n) clustering the simulation results, wherein the clustering comprises a plurality of clusters, each cluster in the plurality of clusters representing models from the performing m); o) selecting representative models of each cluster in the plurality of clusters; p) refining the representative models of the selecting o) by energy minimization; and q) selecting the lowest energy refined representative model as the predicted structure of the amino acid sequence.
US Pat. No. 11,026,996

HUMAN NOTCH1 BASED FUSION PROTEINS AS DECOY INHIBITORS OF JAGGED-NOTCH SIGNALING AND DLL-NOTCH SIGNALING

The Trustees of Columbia ...

1. A fusion protein, the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of amino acids in:(a) an extracellular domain of a human Notch1 receptor protein, followed by
(b) an Fc portion of an antibody,
wherein the extracellular domain of the human Notch1 receptor protein
(i) commences with the amino acid present at the N-terminus of EGF-like repeat 10 and
(ii) extends to and includes the C-terminal amino acid of EGF-like repeat 18 as the C-terminal amino acid of the extracellular domain.
US Pat. No. 11,031,095

ASSAY SYSTEMS FOR DETERMINATION OF FETAL COPY NUMBER VARIATION

Ariosa Diagnostics, Inc.,...

1. A method for determining a likelihood of the presence or absence of a copy number variation (CNV) in a fetal genomic region in a maternal sample from a pregnant female, comprising:a) obtaining the maternal sample from the pregnant female, the maternal sample comprising a fetal source and a maternal source;
b) executing, by a CNV processing system, a process for determining the likelihood of the presence or absence of CNV in the fetal genomic region, the process comprising the following steps:
1) interrogating at least twenty polymorphic loci in a first fetal genomic region in the maternal sample and interrogating at least twenty polymorphic loci in a second fetal genomic region of the maternal sample;
2) determining fetal DNA contribution to the maternal sample;
3) calculating an estimated dosage of the first fetal genomic region in the maternal sample and calculating an estimated dosage of at least the second fetal genomic region in the maternal sample; and
4) comparing the estimated dosages of the first and second fetal genomic regions to determine the likelihood of the presence or absence of the CNV in the first fetal genomic region in view of the fetal DNA contribution to the maternal sample; and
c) assisting in a communication of the determined likelihood of the presence or absence of the CNV in the first fetal genomic region to the pregnant female.
US Pat. No. 11,026,997

TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN

Regeneron Pharmaceuticals...

1. A method of treating recurrent pericarditis comprising administering subcutaneously to a patient in need of treatment, a loading dose of an interleukin-1 receptor-Fc fusion protein at 320 mg, followed by a maintenance dose of the interleukin-1 receptor-Fc fusion protein at 160 mg once weekly, wherein the interleukin-1 receptor-Fc fusion protein is rilonacept.
US Pat. No. 11,028,277

CHARGE TRANSPORT VARNISH

NISSAN CHEMICAL CORPORATI...

1. A charge-transporting varnish comprising a charge-transporting substance, an electron-accepting dopant substance and an organic solvent, wherein the electron-accepting dopant substance includes at least one compound selected from the group consisting of 1,5-naphthalenedisulfonic acid, 2,7-naphthalenedisulfonic acid, 1,3,5-naphthalenetrisulfonic acid, 1,3,6-naphthalenetrisulfonic acid; and 1,4,5,7-naphthalenetetrasulfonic acid, andwherein the charge-transporting substance is a charge-transporting substance having a molecular weight of from 200 to 2,000.
US Pat. No. 11,031,096

METHOD FOR DETERMINING EFFICACY OF CHEMOTHERAPY TREATMENT FOR A SUBJECT

RNA DIAGNOSTICS INC., To...

1. A method for treating a subject with cancer wherein the method comprises:a) treating the subject with a cytotoxic treatment selected from a chemotherapeutic, a neo-adjuvant hormonal, a cytotoxic antibody and/or a radiation treatment regimen;
b) obtaining a unique biological sample comprising cellular ribonucleic acids (RNA) from the subject after having been treated with the cytotoxic treatment, the cytotoxic treatment selected from a chemotherapeutic, neo-adjuvant hormonal, cytotoxic antibody and/or radiation treatment regimen;
c) separating the cellular RNA by electrophoresis, detecting a quantity of the separated cellular RNA, plotting the quantity of separated cellular RNA and obtaining at least one electropherogram dataset from the electropherogram plot;
d) obtaining a plurality of electropherogram datasets including the at least one electropherogram dataset from a data input device, the plurality of electropherogram datasets corresponding to a plurality of unique biological samples comprising cellular RNA;
e) employing a processor that is coupled to the data input device, wherein the processor is configured to analyze the plurality of electropherogram datasets by:
e-i) defining two identifying ranges by initializing the identifying ranges to default ranges, and
e-i-1) performing shifting when a marker region is not at an expected location, where the expected location is a time associated with a first peak that is a dye-only peak that indicates a start of a run of a gel during the electrophoresis for obtaining the at least one electropherogram dataset and the shifting is done so that the two identifying ranges include a shifted 18S peak and a shifted 28S peak, respectively, which are an 18S rRNA peak and a 28S rRNA peak, respectively, or
e-i-2) maintaining the two identifying ranges at the default ranges when the marker region is at the expected location; e-ii) identifying the 18S peak and 28S peak by selecting from possible peak candidates in the two identifying regions where the possible peak candidates are identified by searching for local maximums in the at least one electropherogram;
e-iii) calculating values including one or more of a peak height, a peak width and a peak position based on the identified 18S peak and 28S peak;
e-iv) identifying a standard sample from the plurality of electropherogram datasets using the values calculated from the identified 18S peak and 28S peak and area values for neighboring regions, where the standard sample is a sample of intact RNA or approximately intact RNA after treatment;
e-v) separating the plurality of electropherogram datasets into an adjustment group and a standard group by comparing retention times for both the 28S peak and the 18S peak of the electropherogram dataset of the standard sample with retention times of the 28S peak and the 18S peak of the electropherogram datasets of the other samples;
e-vi) identifying normal characteristics representative of the standard sample from the plurality of electropherogram datasets in the standard group, the normal characteristics comprising the retention times for the 18S peak and the 28S peak from samples in the standard group which are defined as standard retention times;
e-vii) determining locations of the 18S peak and the 28S peak for the electropherogram datasets in the adjustment group by determining retention times for the 18S and 28S peaks of the electropherograms in the adjustment group where these peaks have areas that include the standard retention times for the 18S and 28S peak;
e-viii) determining an intermediate region and a low C banding region for the electropherogram datasets in the adjustment group after locating the 18S peak and the 28S peak in the adjustment group, where the intermediate region is between the located 18S peak and the located 28S peak and the low C banding region is an upper portion of a low banding region below the 18S peak and adjacent to the 18S peak;
e-ix) determining values for features from the electropherograms from the adjustment group after locating the 18S peak and the 28S peak from the electropherograms from the standard group, the features comprising at least one of intermediate region area and low C banding region area, and at least one of 28S peak area, and 18S peak area;
e-x) determining an RNA disruption assay (RDA) score based on a ratio using the values of the features, the RDA score being indicative of the extent of treatment induced RNA degradation; and
e-xi) outputting the RDA score to a data output device that is coupled to the processor;
f) assessing response to the cytotoxic treatment by comparing the RDA score to at least one threshold value or at least one threshold curve to determine when the subject is a responder or a non-responder to the cytotoxic treatment; and
g-i) continuing administration of the cytotoxic treatment when the subject is determined to be a responder; or
g-ii) switching the cytotoxic treatment when the subject is determined to be a non-responder, wherein switching the cytotoxic treatment comprises increasing a dose of the cytotoxic treatment administered, adding one or more of radiation and a chemotherapeutic agent to the cytotoxic treatment regimen, discontinuing the cytotoxic treatment and initiating a different cytotoxic treatment regimen.
US Pat. No. 11,026,998

SHAPED MASS COMPOSITION COMPRISING EXENATIDE

Rani Therapeutics, LLC, ...

1. A shaped mass comprising exenatide for treatment of diabetes or other glucose regulation disorder, wherein a weight percentage of exenatide in the shaped mass is at least about 60%, and wherein at least about 80% of the exenatide in the shaped mass is biologically active, the shaped mass having a density in a range of about 0.95 to about 1.15 mg/mm3, wherein the shaped mass further comprises an excipient.
US Pat. No. 11,028,278

SINGLE PHASE WATER BASED ENERGY CURABLE COMPOSITIONS AND METHOD OF PREPARING COATINGS AND PRINTING INKS

Sun Chemical Corporation,...

1. An energy curable aqueous composition comprising:(a) water;
(b) an ethylenically unsaturated oligomer; and
(c) a water soluble ethylenically unsaturated resin containing neutralized basic functional groups;
wherein the resulting composition is a single phase composition; and wherein the ethylenically unsaturated oligomer is partially water soluble.
US Pat. No. 11,031,097

SYSTEM FOR GENOMIC DATA PROCESSING WITH AN IN-MEMORY DATABASE SYSTEM AND REAL-TIME ANALYSIS

Hasso-Plattner Institut f...

1. A computer-based system comprising:a cluster of computing nodes, each of the computing nodes including a plurality of central processing unit cores;
a non-transitory computer-readable storage medium in communication with the cluster of the computing nodes and configured as an in-memory database system (IMDB);
the non-transitory computer-readable storage medium storing process logic, the process logic, when executed, causing:
at least two of the computing nodes to process nucleotide sequence data in parallel based on annotation data and to store the annotation data and all results and intermediate results from the at least two of the computing nodes in the IMDB, the annotation data including information required to interpret individual genetic dispositions; and
at least one of the computing nodes to:
import the nucleotide sequence data from a sequencer machine (M) into the IMDB, the nucleotide sequence data being provided as reads in the IMDB and being processed concurrently to sequencing the nucleotide sequence data in the sequencer machine (M);
determine whether external sources include updated annotation data not included in the annotation data stored in the IMDB;
upon determining that the external sources include updated annotation data, automatically download and import the updated annotation data from the external sources into the IMDB concurrently to processing the nucleotide sequence data thereby making the updated annotation data available for the processing of the nucleotide sequence in real-time;
segment the reads into chunks;
determine a workload of each of the at least two computing nodes;
assign the chunks to respective computing nodes of the at least two computing nodes based upon the workload of each of the at least two of the computing nodes.
US Pat. No. 11,026,999

INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION

SANOFI-AVENTIS DEUTSCHLAN...

1. A method for improving glycemic control in a patient with type 2 diabetes mellitus inadequately controlled by treatment with insulin glargine and metformin, the method comprising administering to the patient in need thereof a therapeutically effective amount of a fixed ratio combination of:(a) lixisenatide or a pharmaceutically acceptable salt thereof, and
(b) insulin glargine or a pharmaceutically acceptable salt thereof,
wherein the fixed ratio combination is administered as a single daily injection;
wherein the patient has been treated with metformin at a stable dose of at least 1.5 g per day for at least 3 months and has a HbA1c level between 7% and 10%;
such that the administration of the fixed ratio combination improves glycemic control in the patient over treatment with insulin glargine and metformin.
US Pat. No. 11,028,279

COREACTIVE MATERIALS AND METHODS FOR THREE-DIMENSIONAL PRINTING

PPG Industries Ohio, Inc....

1. A composition for three-dimensional printing, comprising:a first component comprising a first compound, wherein the first compound comprises at least one first functional group; and
a second component comprising a second compound, wherein the second compound comprises at least one second functional group,
wherein the at least one second functional group is reactive with the at least one first functional group;
wherein at least one of the first functional group and the second functional group comprises a saturated functional group;
wherein each of the first functional group and the second functional group does not comprise an ethylenically unsaturated group; and
wherein the first component and the second component are mixed to form an extrusion comprising a cross-sectional profile.
US Pat. No. 11,028,535

FIRE SUPPRESSING PLEATED PACKAGING PAPER AND METHOD OF MANUFACTURING

Packaging and Crating Tec...

1. A method of producing pleated paper with fire suppressive characteristics comprising:a. providing Kraft paper for pleating having a weight of 25 to 50 pounds, and Kraft paper for planar support having a weight of approximately 40 to 60 pounds;
b. applying a fire suppressive ink to surfaces of the Kraft papers;
c. pleating the Kraft paper having a weight of 25 to 50 pounds so that the apices of each pleat have an angle of about 88 to 92° and a height ranging from approximately 3/32 of an inch to about ? of an inch; and
d. bonding the pleated paper to at least one sheet of Kraft paper having a weight of approximately 40 to 60 pounds for planar support.
US Pat. No. 11,029,303

PAH ANTIBODIES AND USES THEREOF

THE ADMINISTRATORS OF THE...

1. A recombinant antibody or fragment thereof that specifically binds to a polycyclic aromatic hydrocarbon (PAH), wherein the PAH is selected from the group consisting of naphthalene, acenapthene, acenapthylene, phenanthrene, fluorene, anthracene, benz[a]anthracene, chrysene, pyrene, fluoranthene, benzo[b]fluoranthene, benzo[k]fluoranthene, benzo[a]pyrene, indeno[1,2,3-cd]pyrene, benzol[ghi]perylene, and dibenz[a,h]anthracene,wherein the recombinant antibody or fragment thereof comprises
a) a heavy chain with three CDRs comprising the amino acid sequences GYTFTSYWMH (SEQ ID NO: 60), EINPRNGRSNYNEKFKN (SEQ ID NO: 61), and DGGDY (SEQ ID NO: 62), respectively, and a light chain with three CDRs comprising the amino acid sequences KASQDVGTAVA (SEQ ID NO: 63), WASTRHT (SEQ ID NO: 64), and QQYSSYPLT (SEQ ID NO: 65), respectively;
b) a heavy chain with three CDRs comprising the amino acid sequences GNTFTSYTMH (SEQ ID NO: 69), YINPSSGYTEYNQKFKD (SEQ ID NO: 70), and GPRY (SEQ ID NO: 71), respectively, and a light chain with three CDRs comprising the amino acid sequences KASQNVGTNVA (SEQ ID NO: 72), SASYRYS (SEQ ID NO: 73), and QQYNSYPYT (SEQ ID NO: 74), respectively;
c) a heavy chain with three CDRs comprising the amino acid sequences GYTFTSYWMH (SEQ ID NO: 145), EINPSNGRTNYNEKFKS (SEQ ID NO: 77), and DGGDY (SEQ ID NO: 78), respectively, and a light chain with three CDRs comprising the amino acid sequences KASQDVGTAVA (SEQ ID NO: 79), WASTRHT (SEQ ID NO: 80), and QQYSSYPLT (SEQ ID NO: 81), respectively;
d) a heavy chain with three CDRs comprising the amino acid sequences GYTFTSYWIVH (SEQ ID NO: 85), EINPRNGRSNYNEKFKN (SEQ ID NO: 86), and DGGDY (SEQ ID NO: 87), respectively, and a light chain with three CDRs comprising the amino acid sequences KASQNVGTNVA (SEQ ID NO: 88), SASYRYS (SEQ ID NO: 89), and QQYNSYPLT (SEQ ID NO: 90), respectively;
e) a heavy chain with three CDRs comprising the amino acid sequences GYTFTSYWIVH (SEQ ID NO: 94), EINPRNGRSNYNEKFKN (SEQ ID NO: 95), and DGGDY (SEQ ID NO: 96), respectively, and a light chain with three CDRs comprising the amino acid sequences KASQDVGTAVA (SEQ ID NO: 97), WASTRHT (SEQ ID NO: 98), and XQYXXYPLT (SEQ ID NO: 99), respectively;
f) a heavy chain with three CDRs comprising the amino acid sequences GYAFTKYLIE (SEQ ID NO: 103), VINPGSGSTSYNEKFRY (SEQ ID NO: 104), and IPASYRSDSLDC (SEQ ID NO: 105), respectively, and a light chain with three CDRs comprising the amino acid sequences KASQDVGTAVA (SEQ ID NO: 106), WASTRHT (SEQ ID NO: 107), and QQYSSYPWT (SEQ ID NO: 108), respectively;
g) a heavy chain with three CDRs comprising the amino acid sequences GYTFTKYLIE (SEQ ID NO: 112), VINPGSGSTSYNEKFRYK (SEQ ID NO: 113), and IPASYRSDSLDC (SEQ ID NO: 114), respectively, and a light chain with three CDRs comprising the amino acid sequences KASQDVGTAVA (SEQ ID NO: 115), WASTRHT (SEQ ID NO: 116), and QQYSSYPWT (SEQ ID NO: 117), respectively;
h) a heavy chain with three CDRs comprising the amino acid sequences GYAFTKYLIE (SEQ ID NO: 121), VINPGSGSTSYNEKFRY (SEQ ID NO: 122), and IPASYRSDSLDC (SEQ ID NO: 123), respectively, and a light chain with three CDRs comprising the amino acid sequences KASQDVGTAVA (SEQ ID NO: 124), WASTRHT (SEQ ID NO: 125), and QQYKSYPLT (SEQ ID NO: 126), respectively;
i) a heavy chain with three CDRs comprising the amino acid sequences GYVFTNFLIE (SEQ ID NO: 130), VINPGNGGAAYNEKFKG (SEQ ID NO: 131), and LPPSYDYDGDIDY (SEQ ID NO: 132), respectively, and a light chain with three CDRs comprising the amino acid sequences RASKSVTTSGYSLMH (SEQ ID NO: 133), PASNLES (SEQ ID NO: 134), and QHSRELPWT (SEQ ID NO: 135), respectively; or
j) a heavy chain with three CDRs comprising the amino acid sequences GYAFTNFLIE (SEQ ID NO: 139), VINPGSGGTGYNEKFKG (SEQ ID NO: 140), and LPPSYDYDGDIDY (SEQ ID NO: 141), respectively, and a light chain with three CDRs comprising the amino acid sequences RASKSVSSSGYSLIH (SEQ ID NO: 142), LASNLXS (SEQ ID NO: 143), and XHSXXLPWX (SEQ ID NO: 144), respectively.
US Pat. No. 11,031,098

COMPUTER SYSTEMS AND METHODS FOR GENOMIC ANALYSIS

Genetic Technologies Limi...

1. A system for genomic analysis to determine pharmacogenomic-related genetic loci without a priori knowledge of the location of said loci, the system comprising:one or more databases that store information obtained from genotyping genomic DNA of individuals in a case population which comprises individuals who exhibit a response to a drug to determine frequency of one or more informative genetic variations in the case population and information obtained from genotyping genomic DNA of individuals in a control population which comprises individuals who do not exhibit the response to the drug to determine frequency of one or more informative genetic variations in the control population, wherein the one or more informative genetic variations distinguish one haplotype pattern from other haplotype patterns of a haplotype block;
a server comprising:
one or more processors; and
a computer memory comprising processor-executable instructions that, when executed by the one or more processors, cause the one or more processors to perform the following:
access the one or more databases;
compare frequencies of the one or more informative genetic variations between the case population and the control population;
select the one or more informative genetic variations which have a frequency in the case population which is significantly different to the control population as pharmacogenomic-related genetic loci; and
provide a report to a client device in communication with the server across a communications network, wherein the report includes a description of the one or more informative genetic variations which have a frequency in the case population which is significantly different to the frequency in the control population as pharmacogenomic-related genetic loci.
US Pat. No. 11,027,000

AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE

Voyager Therapeutics, Inc...

1. A polynucleotide comprising:a) a 5? inverted terminal repeat (ITR), wherein said 5? ITR is 141 nucleotides in length,
b) a cytomegalovirus (CMV) sequence region comprising from 5? to 3? a CMV enhancer or a fragment thereof comprising at least 250 nucleotides, and a CMV promoter or a fragment thereof comprising at least 150 nucleotides,
c) an immediate early 1 (IE1) sequence region comprising an IE1 exon1 or a fragment thereof of at least 50 nucleotides, and an IE1 intron 1 or a fragment thereof of at least 20 nucleotides,
d) a human beta globin (HB) sequence region comprising an HB intron 2 or a fragment thereof of at least 250 nucleotides, and an HB exon 3 or a fragment thereof of at least 40 nucleotides,
e) a polynucleotide sequence encoding Aromatic L-Amino Acid Decarboxylase (AADC) or an isoform thereof,
f) a poly(A) signal sequence region comprising a human growth hormone (hGH) poly(A) signal or a fragment thereof of at least 200 nucleotides, and
g) a 3? ITR, wherein said 3? ITR is 141 nucleotides in length;
wherein the polynucleotide comprises a nucleotide sequence at least 95% identical to SEQ ID NO: 17.
US Pat. No. 11,031,099

DETECTION OF SEQUENCE VARIANTS

Roche Molecular Systems, ...

1. A method of detecting at least two nucleic acid sequence variants of a locus in a sample, the method comprising the steps:(a) amplifying, with a Polymerase Chain Reaction (PCR) system comprising a processor, the at least two sequence variants of the locus to produce at least two amplification products including a first variant amplicon and a second variant amplicon, wherein the amplifying step yields a first and second growth curve, respectively, for the first and second amplicons;
(b) analyzing, using the processor, the first and second growth curves by calculating deltaB1 for the first growth curve and calculating deltaB2 for the second growth curve, wherein deltaBn=(maximum|?i?yi|/yMedian), and calculating a relative deviation from linearity ratio comprising deltaB1/deltaB2;
(c) comparing, using the processor, the relative deviation from linearity ratio to a sequence-specific threshold matrix for the locus; and
(d) identifying, using the processor, the two or more sequence variants based on said comparing step (c).
US Pat. No. 11,027,001

THERAPEUTIC CANCER VACCINES DERIVED FROM A NOVEL DENDRITIC CELL LINE

DCPRIME B.V., Leiden (NL...

1. A method for obtaining modified cells, the method comprising:incubating a precursor cell line as deposited at the DSMZ under accession number DSMZ ACC3189 on Nov. 15, 2012, under conditions that allow differentiation of the precursor cells into immature cells; and
incubating the immature cells under conditions that allow maturation of the immature cells into modified cells, wherein the modified cells are CD34-positive, CD1a-positive, CD83-positive, and CD14-negative.
US Pat. No. 11,028,281

FREE RADICAL POLYMERIZABLE WATER-BASED INKJET COMPOSITIONS

Sun Chemical Corporation,...

1. A free radically polymerizable water-based inkjet composition comprising:water;
a water-soluble or water-dispersible component polymerizable by free radical polymerization; and
one or more water-soluble organic solvents in compliance with following Formula I:
?(Xn·Hn·Bn)??  (I)
wherein each individual n represents a water-soluble organic solvent present in the composition;
n is an integer?1;
Xn is the amount on a weight basis of each water-soluble organic solvent present in the composition expressed as 100(wn/wtotal);
wn is the weight of a water-soluble organic solvent present in the composition represented by a value of n;
wtotal is the weight of the ink jet composition;
Hn is Heat of Vaporization of each water-soluble organic solvent (J/g);
Bn=Boiling Point of each water-soluble organic solvent (° C.);
?=sum of the multiplication products of Xn, Hn and Bn for each water-soluble organic solvent present in the composition; and
? is 2,000,000;
wherein the total amount of water-soluble organic solvents in the composition is 10 wt % to 40 wt %, based on the total weight of the composition; and wherein the composition comprises less than or equal to 2.5 wt % water-soluble organic solvents having boiling points of 150° C. or greater and heats of vaporization of equal to or greater than 400 J/g.
US Pat. No. 11,031,100

SIZE-BASED SEQUENCING ANALYSIS OF CELL-FREE TUMOR DNA FOR CLASSIFYING LEVEL OF CANCER

The Chinese University of...

1. A method of analyzing a biological sample of an organism, the biological sample including DNA fragments originating from normal cells and potentially from cells associated with cancer, wherein at least some of the DNA fragments are cell-free in the biological sample, the method comprising:for each of a plurality of DNA fragments from the biological sample:
receiving one or more sequence reads obtained from a sequencing of the DNA fragment, the one or more sequence reads including both ends of the DNA fragment;
aligning the one or more sequence reads to a reference genome to obtain aligned locations for both ends of the DNA fragment; and
using the aligned locations to determine a size of the DNA fragment;
for each size of a plurality of sizes, determining an amount of a first set of the plurality of DNA fragments from the biological sample corresponding to the size using the sizes determined from the aligned locations for the first set;
calculating a first value of a first parameter based on the amounts of DNA fragments at multiple sizes, the first parameter providing a statistical measure of a size profile of DNA fragments in the biological sample;
comparing the first value to a reference value; and
determining a classification of a level of cancer in the organism based on the comparison.
US Pat. No. 11,027,002

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of eliciting an immune response in a patient who has cancer overexpressing a COL12A1 polypeptide comprising the amino acid sequence SYSIGIANF (SEQ ID NO: 57), comprising administering to said patient a population of activated T cells that kill the cancer cells,wherein the activated T cells are cytotoxic CD8+ T cells produced by contacting T cells with an antigen presenting cell that presents a peptide consisting of the amino acid sequence of SYSIGIANF (SEQ ID NO: 57) in a complex with an MHC class I molecule on the surface of the antigen presenting cell in vitro, for a period of time sufficient to activate said T cell,
wherein the cancer is lung cancer or brain cancer.
US Pat. No. 11,028,282

PROCESS FOR BONDING HYDROPHOBIC SURFACES HAVING CATIONIC GUAR-CONTAINING PRIMER COATING THEREON

Rhodia Operations, Paris...

1. A process for bonding two hydrophobic surfaces, the process comprising:(E1) contacting the two surfaces at least on certain zones with a primary coating composition consisting essentially of a cationic polysaccharide, wherein the cationic polysaccharide is a cationic guar, and wherein the composition is free of ionic surfactant, whereby a coating based on said cationic polysaccharide is obtained on said zones of the surfaces,
(E2) injecting an aqueous composition, wherein the aqueous composition is an adhesive, between all or part of the zones of the surfaces covered by the cationic polysaccharide, as obtained in step (E1).
US Pat. No. 11,028,538

COMPOSITION AND METHOD FOR INCREASING WET AND DRY PAPER STRENGTH

SOLENIS TECHNOLOGIES, L.P...

1. A composition for increasing paper strength, said composition comprising:A. a dialdehyde-modified polyacrylamide strengthening agent; and
B. a water soluble compound that comprises one or more hydroxyl or amide moieties and that is soluble at 5 wt % or greater in water at 25° C., and
C. water present in an amount of less than 10 wt %,
wherein said water soluble compound is present in a weight amount that is greater than a weight amount of said dialdehyde-modified polyacrylamide strengthening agent, and
wherein said composition is powdered and has a shelf-life of at least six months such that wet strength and/or dry strength paper performance after six months is at least 80% of wet strength and/or dry strength paper performance measured within one month of manufacture of said composition.
US Pat. No. 11,027,003

HLA-DR-BINDING ANTIGEN PEPTIDE DERIVED FROM WT1

INTERNATIONAL INSTITUTE O...

1. A peptide consisting of the amino acid sequence of SEQ ID NO: 24.
US Pat. No. 11,027,259

PREPARATION METHOD FOR HOLLOW MOLYBDATE COMPOSITE MICROSPHERES AND METHOD FOR CATALYZING AMMONIA BORANE HYDROLYSIS TO PRODUCE HYDROGEN

HUIZHOU UNIVERSITY, Huiz...

1. A method for preparing hollow molybdate composite microspheres, comprising steps of:(1) dissolving 1-4 mmol of MCl2 in 20 ml of water to obtain a solution A, and dissolving 1-4 mmol of molybdic acid in 20 ml of water to obtain a solution B, followed by mixing the solution A and the solution B to obtain a mixed solution C, in which M being at least one of Co, Ni, or Cu;
(2) dissolving 10-40 mmol of urea in 40 ml of water, adding the mixed solution C of step (1) and stirring uniformly to obtain a solution D;
(3) transferring the mixed solution D of step (2) into a reaction vessel and reacting at 120-160° C. for 6-12 hours to obtain product E;
(4) carrying out suction filtration and water washing to the product E, followed by drying in a vacuum oven at 40-60° C. to obtain a solid; and
(5) calcining the solid at 350-500° C. for 2 to 4 hours in a muffle furnace to obtain hollow molybdate composite microspheres.
US Pat. No. 11,028,027

PROCESS FOR PRODUCING 2-CHLORO-3,3,3-TRIFLUOROPROPENE

ARKEMA FRANCE, Colombes ...

1. A process for the production of 2-chloro-3,3,3-trifluoropropene comprising the stages of:a) providing a stream A comprising at least one of the compounds selected from the group consisting of 2,3-dichloro-1,1,1-trifluoropropane, 1,1,1,2,3-pentachloropropane, 1,1,2,3-tetrachloropropene and 2,3,3,3-tetrachloropropene;
b) in a reactor, bringing said stream A into contact with HF in the presence or absence of a catalyst in order to produce a stream B comprising 2-chloro-3,3,3-trifluoropropene;
wherein the electrical conductivity of said stream A provided in stage a) is less than 15 mS/cm.
US Pat. No. 11,028,283

SUBSTRATE HAVING A FUNCTIONAL COATING AND A TEMPORARY PROTECTION LAYER

SAINT-GOBAIN GLASS FRANCE...

1. An article comprising a substrate comprising two main faces defining two main surfaces separated by edges, said substrate bearing:a functional coating deposited by magnetron sputtering deposited on at least one portion of one main surface, said functional coating including an upper layer having a thickness from 1 nm to 40 nm, and
a temporary protective layer deposited on at least one portion of the functional coating, wherein,
the temporary protective layer is deposited directly in contact with the upper layer of the functional coating,
the temporary protective layer has a thickness of at least 1 micrometer,
the temporary protective layer is not soluble in water, and
the temporary protective layer is obtained from a composition comprising (meth)acrylate compounds,
the substrate bearing the functional coating has not undergone a heat treatment at a temperature above 400° C.
US Pat. No. 11,028,539

SOFT HIGH BASIS WEIGHT TISSUE

KIMBERLY-CLARK WORLDWIDE,...

1. A creped wet pressed tissue product comprising a first creped wet pressed tissue ply having a basis weight greater than 20 grams per square meter (gsm) and a second creped wet pressed tissue ply having a basis weight greater than 20 gsm, wherein the tissue product has a geometric mean tensile (GMT) from about 600 to about 1,000 g/3? and a Stiffness Index less than about 20.
US Pat. No. 11,031,102

RISK EVALUATION AND MANAGEMENT STRATEGY INVOLVING PATIENT FOLLOW-UPS RELATING TO THE USE OR DISCONTINUATION OF A COMPLEMENT INHIBITOR

Alexion Pharmaceuticals, ...

1. A method of treating a patient in need of treatment with eculizumab or an eculizumab variant, or inhibiting complement activation in a patient, and then monitoring the patient after administration of the eculizumab or the eculizumab variant has ceased, comprising:certifying a prescriber to become a certified prescriber of the eculizumab or the eculizumab variant by:
first requesting via a computing device employing a processor that a provider become authorized to prescribe the eculizumab or the eculizumab variant;
the provider then verifying via the computing device that the prescriber has agreed to the following conditions:
(a) to vaccinate and/or revaccinate patients receiving the eculizumab or the eculizumab variant, at predetermined times or intervals, with one or more meningococcal vaccines during treatment, including a Neisseria meningococcal type B specific vaccine, to prevent a meningococcal infection;
(b) to provide patients with educational materials regarding the eculizumab or the eculizumab variant, and
(c) that the prescriber has reviewed information provided by the provider relating to the eculizumab or the eculizumab variant;
once verified, adding said prescriber to the database as the certified prescriber via the computing device in order to counsel the patient with regard to the risks associated with the eculizumab or the eculizumab variant and is vaccinated or revaccinated to prevent the meningococcal infection, and that the prescriber is educated with regard to administering the eculizumab or the eculizumab variant to the patient;
generating via the computing device a prescription approval code and authorizing the prescriber to prescribe to the patient the eculizumab or the eculizumab variant only if the prescriber is in the database of certified prescribers,
administering an effective amount of the eculizumab or the eculizumab variant to said patient who has been prescribed the eculizumab or the eculizumab variant by the certified prescriber,
monitoring the patient during and after administration of the eculizumab or the eculizumab variant for an adverse medical event including a thrombotic microangioplasty (TMA) event, and if administration of the eculizumab or the eculizumab variant to the patient has ceased and the TMA event occurs, then alerting the patient via the computing device to seek treatment for the TMA event, and then
treating the patient for the TMA event.
US Pat. No. 11,027,004

IMMUNOGENIC COMPOSITIONS CONTAINING BACTERIAL OUTER MEMBRANE VESICLES

BIOMVIS SRL, Siena (IT)

1. A method of preparing an outer membrane vesicle (OMV) from a Gram-negative bacterium, whereinsaid OMV comprises a lipoprotein consisting of a heterologous protein which is a bacterial, viral, parasitic, cancer protein or polypeptide-carrying an acylated N-terminal cysteine,
said heterologous protein is fused to a lipoprotein leader sequence, said lipoprotein leader sequence causing said heterologous proteins to become lipidated,
and
said OMV is capable of eliciting an immune response to the heterologous protein when administered to a mammal,
said method comprising the following steps:
(i) expressing, in a Gram-negative bacterium, the heterologous protein fused to said leader sequence carrying a C-terminal Cysteine, wherein the leader sequence comprises the sequence Leu-(Ala/Ser)-(Gly/Ala)-Cys (lipobox), SEQ ID NO:111; and
(ii) isolating the OMV containing the heterologous protein.
US Pat. No. 11,028,028

PROCESS FOR PREPARING 3,3,3-TRIFLUOROPROP-1-ENE

THE CHEMOURS COMPANY FC, ...

1. A composition comprising:i) 3-chloro-1,1,1-trifluoropropane (253fb); and
ii) 1,1,1,3-tetrafluoropropane (254fb).
US Pat. No. 11,029,308

METHODS FOR VAPOR DETECTION AND DISCRIMINATION WITH MAMMALIAN ODORANT RECEPTORS EXPRESSED IN HETEROLOGOUS CELLS

DUKE UNIVERSITY, Durham,...

1. A method of identifying an odorant receptor ligand comprising the steps of:a) providing a biological sample comprising cells expressing at least one odorant receptor and exposing the biological sample to at least one test compound in a vapor/gaseous phase,
wherein the one or more odorant receptors at least includes olfr145,
wherein the biological sample further expresses at least one of the following:
one or more proteins known to enhance cell surface localization of the odorant receptors selected from REEP1, RTP1 and RTP2,
one or more odorant receptor binding proteins selected from Lcn3, Lcn4, Lcn10, Lcn11, OBP1a, OBP1b, and OBP2b, and
one or more metabolic enzymes, wherein the one or more metabolic enzymes at least includes carboxyl esterase;
b) measuring a signal that is proportional to activation of one of the odorant receptors in said biological sample, and
c) comparing the measured level of activation of one of the odorant receptors determined in step b) to a reference activation level for the specific odorant receptor determined in the same conditions with a negative control where the biological sample has not been exposed to said at least one test compound in a vapor/gaseous phase.
US Pat. No. 11,027,005

METHOD FOR PRODUCING HIB CONJUGATE VACCINE USING PRP WITH LOWERED MOLECULAR WEIGHT

KM BIOLOGICS CO., LTD., ...

1. A method for preparing a polyribosylribitol phosphate (PRP) conjugate via a coupling reaction of PRP and a carrier protein wherein the method is characterized by that the release of PRPs after preparing the PRP conjugate is suppressed by using PRP with a lowered molecular weight than native PRP, wherein the PRP conjugate is stored in a solution of pH 5.4 to 6.3 after preparation of the PRP conjugate.
US Pat. No. 11,028,029

PROCESS FOR THE PRODUCTION OF 2,3,3,3-TETRAFLUOROPROPENE

Arkema France, Colombes ...

1. A process for the production of 2,3,3,3-tetrafluoropropene comprising the stages:i. in a first reactor, bringing 2-chloro-3,3,3-trifluoropropene into contact with hydrofluoric acid in the gas phase in the presence of a catalyst, in order to produce a stream A comprising 2,3,3,3-tetrafluoropropene, HF and unreacted 2-chloro-3,3,3-trifluoropropene; and
ii. in a second reactor, bringing hydrofluoric acid into contact, in the gas phase in the presence or absence of a catalyst, with at least one chlorinated compound selected from the group consisting of 1,1,1,2,3-pentachloropropane, 2,3-dichloro-1,1,1-trifluoropropane, 2,3,3,3-tetrachloropropene and 1,1,2,3-tetrachloropropene, in order to produce a stream B comprising 2-chloro-3,3,3-trifluoropropene,wherein the stream A obtained in stage i) feeds said second reactor used for stage ii); and the pressure at the inlet of said first reactor of stage i) is greater than the pressure at the inlet of said second reactor of stage ii).
US Pat. No. 11,028,285

URETHANE (METH)ACRYLATE AND ACTIVE ENERGY RAY-CURABLE RESIN COMPOSITION

DAICELL-ALLNEX LTD., Tok...

1. A urethane (meth)acrylate comprising a cyclic structure in a molecule,wherein the urethane (meth)acrylate is obtained by reacting a polyol (X), a polyisocyanate (Y), and a hydroxy-containing (meth)acrylate (Z),
wherein the polyol (X) comprises an isosorbide,
the urethane (meth)acrylate is prepared by reacting the polyol (X) and the polyisocyanate (Y) to form an isocyanate-containing urethane isocyanate prepolymer, and reacting the urethane isocyanate prepolymer with the hydroxy-containing (meth)acrylate (Z),
the urethane (meth)acrylate has a total weight of carbon, oxygen, nitrogen, and sulfur atoms constituting a ring or rings of the cyclic structure of 10 to 27.2 percent by weight based on the total weight (100 percent by weight) of the urethane (meth)acrylate,
the urethane (meth)acrylate comprises two or more different hydroxy-containing (meth)acrylates,
the urethane (meth)acrylate has an average number of functional groups of 3.5 to 4.5, and
the urethane (meth)acrylate comprising at least one feature selected from the group consisting of (A) and (B):
(A) the cyclic structure includes at least one heterocyclic ring, and
(B) the hydroxy-containing (meth)acrylate (Z) includes hydroxy-containing (meth)acrylates containing a cyclic structure in the molecule.
US Pat. No. 11,029,309

COMPOSITION COMPRISING UP-CONVERTING PHOSPHORS FOR DETECTING AN ANALYTE

Roche Diabetes Care, Inc....

1. A covering layer matrix, comprising:a polymeric film former and up-converting phosphor particles;
wherein the covering layer matrix is adapted for use as a reflecting layer in a two- or more layer test element;
a strongly light-scattering agent;
wherein the covering layer matrix lacks an indicator reagent; and
wherein the covering layer matrix is configured to cover a detector matrix having the indicator reagent distributed within the detector matrix.
US Pat. No. 11,027,006

ADENOVIRAL VECTOR VACCINE

VAXum, LLC, Warrenton, V...

1. A viral expression vector composition for generating an antigen specific cellular immune response against cancer cells which are positive for a target antigen by promoting activation of an individual's dendritic cells, said viral expression vector composition comprising a transcription unit encoding a fusion protein comprising a secretable CD40 ligand extracellular domain fused to a secretory signal sequence and a target antigen, wherein the target antigen is attached by a linker to an amino-terminus of the extracellular domain of said CD40 ligand.
US Pat. No. 11,027,262

CATALYST CONTAINING A FURAN COMPOUND AND USE THEREOF IN A HYDROPROCESSING AND/OR HYDROCRACKING METHOD

IFP Energies Nouvelles, ...

1. A catalyst comprising a support based on alumina or silica or silica-alumina, at least one Group VIII element, at least one Group VIB element and a furan compound.
US Pat. No. 11,028,286

DUAL CURABLE SILICONE COMPOSITIONS

Dow Silicones Corporation...

1. A dual curable silicone composition, comprising:(a) a silicone resin comprising at least one epoxy group, wherein the silicon resin is according to formula (I)
[R1R2R3SiO1/2]a[R4R5SiO2/2]b[R6SiO3/2]c[SiO4/2]d,  (I)
where each R1-6 is independently hydrocarbyl, H, hydroxyl, alkoxy, or epoxy-containing group and at least one of R1-6 is an epoxy-containing group, and where a+b+c+d=1 and c+d>0,
(b) a silicone polymer comprising at least one epoxy group and at least one hydrolyzable group, wherein the silicon polymer is according to formula (II)
[R7R8R9SiO1/2]e[R10R11SiO2/2]f,  (II)
where each R7-11 is independently hydrocarbyl, H, hydroxyl, a hydrolyzable group, or epoxy-containing group and at least one of R7-11 group is hydrolyzable group and at least one of one R7-11 group is an epoxy-containing group and wherein e>0 and f>0,
(c) a catalytic amount of onium salt photo catalyst,
(d) a catalytic amount of condensation catalyst,
wherein the composition is curable when exposed to UV radiation, H2O, or UV radiation and H2O.
US Pat. No. 11,027,007

RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE

The United States of Amer...

1. A nucleic acid molecule encoding a recombinant metapneumovirus (MPV) F protein or immunogenic fragment thereof stabilized in a prefusion conformation by one or more amino acid substitutions compared to a native MPV F protein sequence, wherein the recombinant MPV F protein comprises a F2 polypeptide and a F1 ectodomain, wherein the one or more amino acid substitutions introduce one or more non-native intra- or inter-protomer disulfide bonds that, alone or in combination with other modifications, stabilize the MPV F protein in the prefusion conformation.
US Pat. No. 11,027,263

FURAN-2,5-DICARBOXYLIC ACID PURGE PROCESS

Eastman Chemical Company,...

1. A process to produce a raffinate stream in a method for making a carboxylic acid, said process comprising:(i) oxidizing in an oxidation zone an oxidizable raw material stream comprising 5-(hydroxymethyl) furfural (5-HMF) in the presence of an oxidation solvent stream comprising a saturated organic acid having from 2-4 carbon atoms and a catalyst at a temperature of 100° C. to 220° C. to produce a crude carboxylic acid slurry; wherein said oxidation zone comprises at least one oxidation reactor; wherein said crude carboxylic acid slurry comprises furandicarboxylic acid; wherein said catalyst comprises cobalt, manganese and bromine; and wherein the yield of furandicarboxylic acid is greater than 90%;
(ii) routing said crude carboxylic acid slurry to a solid liquid separation zone to produce a mother liquor stream comprising said catalyst and impurities; wherein said solid liquid separation zone comprises at least one pressure drum filter;
(iii) routing at least a portion of said mother liquor stream to a mother liquor purge zone comprising a liquid-liquid extraction zone to produce an extract stream comprising impurities and an extract solvent, and a raffinate stream comprising catalyst solvent and oxidation catalyst; wherein at least a portion of said oxidation catalyst and/or catalyst solvent is optionally recycled to the oxidation zone; and wherein said oxidizable raw material stream comprises greater than 40% by weight of 5-HMF.
US Pat. No. 11,028,031

METHOD FOR PRODUCING HIGH-CONCENTRATION ALCOHOL

MITSUBISHI CHEMICAL CORPO...

1. A method of concentrating ethanol, comprisingintroducing a hydrous ethanol into a membrane separation unit that comprises a zeolite membrane comprising a zeolite with an SiO2/Al2O3 molar ratio of 5 to 15 to obtain a concentrated ethanol having a concentration of at least 80% by mass of ethanol, wherein the membrane separation unit has a permeation of flux of water of 0.1 kg/(m2·h) or more; and
dehydrating the concentrated ethanol with an LTA-type zeolite membrane.
US Pat. No. 11,028,287

MOISTURE-CURABLE OMNIPHOBIC COATINGS

The Government of the Uni...

27. A composition comprising:a polymer made by a method comprising;
providing an alkoxysilane-terminated polyurea;
wherein the alkoxysilane-terminated polyurea is a reaction product of a mixture consisting of an aliphatic polyisocyanate having at least 2 isocyanate groups and an amino-functional alkoxysilane of the formula NH(R3)(CH2)nSi(R2)x(OR1)3-x; wherein n is 1, 2, or 3; wherein x is 0, 1, or 2;
wherein each R1 and R2 is an alkyl group; and
wherein R3 is aryl, alkyl, an ester-containing alkyl, or a fluorinated alkyl group; and
reacting by a moisture-curing reaction the polyurea and a fluorinated material having one or more alkoxy or hydroxyl groups; and an amino-functional alkoxysilane, 3-aminopropyltrimethoxysilane, 3-aminopropyltriethoxysilane, 3-aminopropylmethyldiethoxysilane, or N-methyl-3-aminopropyltrimethoxysilane.
US Pat. No. 11,029,311

METHOD FOR DETERMINING A CONCENTRATION OF EPITHELIAL CELLS IN A BLOOD SAMPLE OR ASPIRATE SAMPLE

1. A method for determining a concentration of epithelial cells in a blood sample or aspirate sample which originates from a human or mammal and has been admixed with an anticoagulant, comprising the following steps:a) lysing the erythrocytes present in the blood sample or aspirate sample by addition of a buffer which brings about a lysis of the erythrocytes, segregating cells which are not lysed in the course of this, and suspending the segregated cells in a buffer, wherein the blood sample or the aspirate sample is stored at a temperature between 0 and 40° C. for at least 24 hours before the erythrocytes are lysed,
b) adding antibodies, antibody fragments or antibody mimetics which each bear at least one label and which are each directed against the epithelial cell adhesion molecule (EpCAM) and/or at least one other antigen specific for epithelial cells to a cell suspension obtained in step a) or to a subquantity of said cell suspension, which subquantity has been obtained by segregation, mixing the antibodies, antibody fragments or antibody mimetics and the cell suspension or the subquantity, and incubating a mixture obtained as a result for at least a time which is required for the attainment of a decreasing binding rate of binding of the antibodies, antibody fragments or antibody mimetics to the cells, wherein the incubation is done for at least 12 hours,
c) determining the number of cells labeled by binding of the antibodies, antibody fragments or antibody mimetics, in the mixture obtained in step b), and
d) calculating the concentration of the labeled cells, the number of which has been determined in step c), in the blood sample or aspirate sample.
US Pat. No. 11,027,008

RECOMBINANT MUMPS VIRUS VACCINE

UNIVERSITY OF GEORGIA RES...

1. A live-attenuated recombinant mumps virus (rMuV) comprising one or more mutations to the V/I/P gene abrogating expression of the V protein compared to a parent mumps virus from which the live-attenuated rMuV is mutated.
US Pat. No. 11,027,264

FLUID CATALYTIC CRACKING CATALYSTS FOR INCREASING BUTYLENE YIELDS

BASF Corporation, Florha...

1. A method of making a microspherical fluid catalytic cracking catalyst, the method comprising:mixing microspheres with a barium solution to form a barium-microsphere mixture; and
calcining the barium-microsphere mixture to form a first calcined material;
wherein:
prior to the mixing with the barium solution, the microspheres comprise Y-zeolite crystallized as a layer on the surface of a porous alumina-containing matrix; and
the mixing with the barium solution is conducted at acidic pH conditions.
US Pat. No. 11,029,312

STABILIZATION OF GLUTAMATE DEHYDROGENASE IN AN AQUEOUS SOLUTION

1. A process for stabilizing glutamate dehydrogenase from a bacterium of the Clostridium genus in order to maintain antigenic properties of the glutamate dehydrogenase, comprising:stabilizing the glutamate dehydrogenase in an aqueous solution comprising (i) a stabilizing compound that is a carboxylic acid having a carbon-based chain of at least three carbon atoms and comprising at least two —COOH groups, or a salt thereof, and (ii) any of a monosaccharide polyol, disaccharide polyol, or polymeric macromolecule in addition to the glutamate dehydrogenase; and
maintaining the antigenic properties of the glutamate dehydrogenase during storage of the aqueous solution, wherein:
the glutamate dehydrogenase is in the aqueous solution at a concentration ranging from 0.75 to 10 ng/ml; and
the aqueous composition has a pH of between 4.5 and 7.
US Pat. No. 11,027,009

VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND COMPOSITIONS AND METHODS OF USING THE SAME

The Trustees of the Unive...

1. An immunogenic pharmaceutical composition comprising:an isolated nucleic acid molecule that encodes an immunogen,
wherein the immunogen is a viral protein, and wherein the nucleic acid molecule further comprises a nucleotide sequence that encodes an IgE signal peptide; and
an isolated nucleic acid molecule that encodes IL-28 or functional fragments thereof.
US Pat. No. 11,027,265

SCR CATALYST

Johnson Matthey Public Li...

1. A one-pot synthesis method for making a catalyst composition comprising a zeolite having a CHA framework, a molar silica-to-alumina ratio (SAR) of 45 to 85, and an atomic copper-to-aluminium ratio of at least 1.25, which method comprising forming a reaction mixture containing a source of silica, a source of alumina, a first CHA framework organic templating agent in the form of a copper metal-amine, a second distinct organic CHA templating agent, and seed crystals; heating the reaction mixture to facilitate crystallization and precipitation of the crystals of the catalyst composition; and collecting, washing and drying the crystals.
US Pat. No. 11,028,033

METHOD FOR PRODUCING TERPENE ALDEHYDES AND TERPENE KETONES

SYMRISE AG, Holxminden (...

1. A method for producing terpene ketones by oxidative dehydrogenation of the corresponding terpene alcohols, the method comprising:bringing starting materials comprising terpene alcohols or terpene alcohol-containing reactants into contact with a heterogeneous ruthenium catalyst to form a mixture;
heating the mixture at a temperature of about 180 to about 320° in the presence of oxygen to form a reaction mixture; and optionally
separating the terpene ketones from the resulting reaction mixture,
wherein a reaction to form the reaction mixture is carried out in a reactor through which a gas stream flows continuously, said gas stream comprising at least one terpene alcohol and an oxygen-containing gas and optionally an inert gas when entering the reactor.
US Pat. No. 11,029,313

METHOD OF TREATING CERVICAL NEOPLASIA IN PATIENTS INFECTED WITH HUMAN PAPILLOMA VIRUS

The General Hospital Corp...

1. A method for treating cervical neoplasia in a subject infected with human papilloma virus (HPV), the method comprising:(a) detecting an HPV status from a cervical sample obtained from the subject, wherein the HPV is HPV type 6, 11, 16, 18, 31, 33, and/or 51;
(b) measuring a level of a CXCL12 polypeptide having a molecular weight greater than about 10 kD or 11 kD in a cervical neoplasia sample of the subject;
(c) comparing the level of the CXCL12 polypeptide in the cervical neoplasia sample of the subject to a first reference level and a second reference level; and
(d) administering a less aggressive treatment to the subject identified as having a pre-invasive cervical neoplasia, wherein the pre-invasive cervical neoplasia comprises a level in the cervical neoplasia sample above the first reference level and below the second reference level, or administering a more aggressive treatment to the subject identified as having an invasive stage of cervical neoplasia, wherein the invasive stage of cervical neoplasia comprises a level in the cervical neoplasia sample above both the first reference level and the second reference level,
wherein the first reference level is an increase of less than about 3-fold compared to a control sample;
wherein the second reference level is an increase of more than 3-fold compared to the control sample;
wherein the less aggressive treatment regimen is selected from the group consisting of loop electrical excision procedure (LEEP), trachelectomy, and hormonal therapy; and
wherein the more aggressive treatment regimen is selected from the group consisting of hysterectomy, radiation therapy, and chemotherapy;
thereby treating the cervical neoplasia in the subject.
US Pat. No. 11,027,010

REDUCTION OF IN VITRO GENOTOXICITY OF POLLEN EXTRACTS BY REMOVAL OF FLAVONOIDS

STALLERGENES, Antony (FR...

1. A pharmaceutical composition comprising a purified pollen extract containing pollen allergen comprising a mixture of cocksfoot, meadow grass, rye-grass, sweet vernal-grass and timothy grass extracts, wherein the composition contains an amount of each flavonoid that is less than 0.002 g per 100 g of pollen derived fraction, as expressed in aglycone equivalent, and a pharmaceutically acceptable carrier comprising a vaccination adjuvant selected from the group consisting of heat-labile enterotoxin, choleratoxin, cholera toxin B subunit, polymerized liposomes, and mutant toxins.
US Pat. No. 11,027,522

STEEL SHEET FOR HOT STAMPING

NIPPON STEEL CORPORATION,...

1. A steel sheet for hot stamping comprisinga steel structure comprising
an area fraction of bainite, fresh martensite and tempered martensite: 80% or more in total, and
a product of a number density of carbides, in pieces/?m2, and a proportion of carbides precipitated into prior austenite grains in carbides: 0.50 or more and 10 or less.
US Pat. No. 11,028,034

METHOD FOR PRODUCING ROTUNDONE-CONTAINING MIXTURES

SYMRISE AG, Holzminden (...

1. A method for manufacturing a mixture comprising rotundone comprising:a) reacting wood oil(s), extract(s) and/or natural resin(s) containing guaiol and bulnesol with one or several organic acid(s),
b) separating a guaiene containing fraction from a mixture obtained in a),
c) oxidizing the separated guaiene containing fraction of b),
d) optionally, heating an oxidized mixture obtained in c), and
e) separating a rotundone containing fraction from the mixture obtained in c) or d), if present, to obtain a rotundone containing mixture.
US Pat. No. 11,029,314

METHODS FOR DIAGNOSIS, DIFFERENTIATION AND MONITORING USING URINE PROTEINS AS MARKERS IN IGA NEPHROPATHY

INSTYTUT BIOCHEMII I BIOF...

1. A method of diagnosis of IgA nephropathy in a human subject, comprising:(a) a step of detecting a combination of alpha-1B-glycoprotein (A1BG), orosomucoid 1 (ORMI), and Ig lambda-2 chain C regions (IGLC2) as protein markers in a urine sample from said human subject, wherein the markers are detected as peptide fragments using mass spectrometry;
(b) a step of quantitative or semi-quantitative comparison of the markers detected in step (a) with the markers detected in a urine sample from a healthy human individual; and
(c) a step of correlating results obtained in step (b) with the presence of IgA nephropathy in the human subject if the levels of all markers in the examined sample from the human subject identified in step (a) are higher than the levels of the same markers present the sample from the healthy human individual.
US Pat. No. 11,027,011

VACCINES WITH BIOMOLECULAR ADJUVANTS

The Trustees of the Unive...

1. A vaccine comprising a nucleotide sequence encoding an antigen selected from the group consisting of: human papilloma virus (HPV) antigen, an HIV antigen, an influenza antigen, and a Plasmodium falciparum antigen, and a nucleotide sequence encoding one or more adjuvants selected from the group consisting of: T-box transcription factor TBX21 (T-bet), Eomesodermin (Eomes), FMS-like tyrosine kinase 3 ligand (FLT3L), TNF-related weak inducer of apoptosis (TWEAK), Glucocorticoid-induced tumor necrosis factor related protein ligand (GITRL) and Stimulator of interferon genes (STING), wherein said nucleotide sequence encoding T-bet comprises a sequence that is 95% identical or greater to SEQ ID NO: 3, said nucleotide sequence encoding Eomes comprises a sequence that is 96% identical or greater to SEQ ID NO:5, said nucleotide sequence encoding FLTL3 comprises a sequence that is 95% identical or greater to SEQ ID NO:7, said nucleotide sequence encoding TWEAK comprises a sequence that is 95% identical or greater to SEQ ID NO:9, said nucleotide sequence encoding GITRL comprises a sequence that is 95% identical or greater to SEQ ID NO:11, and said nucleotide sequence encoding STING comprises a sequence that is 95% identical or greater to SEQ ID NO:13.
US Pat. No. 11,027,267

COBALT COMPOUND USEFUL AS CATALYST FOR HYDROSILYLATION, DEHYDROGENATIVE SILYLATION AND CROSSLINKING OF SILICONE COMPOSITIONS

Elkem Silicones France SA...

1. A process for preparing hydrosilylation and/or dehydrogenative silylation products by reaction between an unsaturated compound A comprising at least one alkene functional group and/or at least one alkyne functional group with a compound B comprising at least one hydrosilyl functional group, wherein said process is catalyzed by a cobalt compound C of formula (1):[Co(N(SiR3)2)x]y  (1)
in which:
the symbols R, which are identical or different, represent a hydrogen atom or a hydrocarbon radical having from 1 to 12 carbon atoms,
x=1, 2 or 3, and
y=1 or 2.
US Pat. No. 11,031,622

LITHIUM-ION SECONDARY BATTERY

CONTEMPORARY AMPEREX TECH...

1. A lithium-ion secondary battery comprising a positive electrode plate, a negative electrode plate, a separator and an electrolyte, the electrolyte comprising a lithium salt and an organic solvent;wherein
the lithium-ion secondary battery satisfies a relationship:2.13?(m×C)/(?×Cap)<2.63, m represents a total mass of the electrolyte inside the lithium-ion secondary battery with a unit of g, ? represents a density of the electrolyte with a unit of g/cm3, C represents a concentration of the lithium salt in the electrolyte with a unit of mol/L, Cap represents a rated capacity of the lithium-ion secondary battery with a unit of Ah,the positive electrode plate comprises a positive current collector and a positive film, the positive film is provided on at least one surface of the positive current collector and comprises a positive active material, the positive active material comprises one or more selected from the group consisting of LixNiaCobMcO2 and a doping and/or coating modified compound thereof, M is one or two selected from the group consisting of Mn and Al, 0.95?x?1.2, 0 the density of the electrolyte represented by ? is 1.1 g/cm3-1.25 g/cm3.
US Pat. No. 11,027,012

ANTIGEN BINDING PROTEINS THAT BIND PD-L1

Sorrento Therapeutics, In...

1. A recombinant fully human anti-PD-L1 antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable domain comprising complementarity determining regions (CDRs) as set forth in the heavy chain variable domain amino acid sequence of SEQ ID NO: 213; and comprising a light chain variable domain comprising CDRs as set forth in the light chain variable domain amino acid sequence of SEQ ID NO: 214.
US Pat. No. 11,027,268

COMPOSITION AND A METHOD OF MAKING AND USE OF SUCH COMPOSITION

Shell Oil Company, Houst...

1. A composition for use in the hydroprocessing of a hydrocarbon feedstock, wherein said composition comprises:a dried and calcined shaped support material that is thereafter impregnated with at least two metal components followed by drying and calcination thereof and thereby providing a metal-incorporated support having available pore volume, and thereafter at least 75% of said available pore volume is filled with a single amide organic additive capable of forming a metal complex with each of said at least two metal components and having a complexation energy of an absolute value of greater than 470 kcal/mol, and
wherein said amide organic additive is selected from the group consisting of formamide, methylformamide, dimethylformamide and diethylformamide, and
wherein said at least two metal components are one metal from a first group of metals consisting of cobalt and nickel, present in said composition in an amount in the range of from 0.5 wt. % to 20 wt. %, and a second metal from a second group of metals consisting of molybdenum and tungsten, present in said composition in an amount in the range of from 5 wt. % to 50 wt. %, wherein the weight percents are based on the weight of the dry support material with the metal component as the elemental form regardless of its actual form, and
wherein said calcined shaped support material is a porous refractory oxide selected from the group of refractory oxides consisting of silica, alumina, titania, zirconia, silica-alumina, silica-titania, silica-zirconia, titania-alumina, zirconia-alumina, and combinations of two or more thereof; and
wherein said support material has a surface area (as determined by the BET method) in the range of from 50 m2/g to 450 m2/g, a mean pore diameter in the range of from 50 to 200 angstroms (?), and a total pore volume exceeding 0.55 cc/g; and wherein less than 7.5% of the total pore volume of said support material is contained in pore having a pore diameter greater than 350 ?.
US Pat. No. 11,027,013

CANCER THERAPY WITH AN ONCOLYTIC VIRUS COMBINED WITH A CHECKPOINT INHIBITOR

DEUTSCHES KREBSFORSCHUNGS...

1. A pharmaceutical combination containing (a) parvovirus H-1 and (b) an anti-PD1 antibody or an anti-PD-L1 antibody.
US Pat. No. 11,028,037

METHOD OF REMOVING NITRATE COMPOUNDS FROM ADIPIC ACID

BASF SE, Ludwigshafen am...

1. A method of removing a nitrate compound from solid adipic acid, said method comprising:i) contacting solid adipic acid comprising a nitrate compound with a gas, wherein the contacting takes place at a temperature in a range of above 85° C. to 95° C.,
wherein i) is either:
a) not followed by any further contacting of the solid adipic acid with a gas wherein the further contacting takes place at a temperature higher than the temperature of i), or
b) followed by further contacting the solid adipic acid with a gas wherein the further contacting takes place at a temperature that is above the temperature of i) above 95° C., but below 100° C.
US Pat. No. 11,028,293

PRESSURE-SENSITIVE ADHESIVE COMPOSITION FOR FOLDABLE DISPLAY

INNOX ADVANCED MATERIALS ...

1. A pressure-sensitive adhesive composition for a foldable display, the pressure-sensitive adhesive composition comprising an acrylic polymer and a crosslinking agent and satisfying the following conditions (1) to (3):60×104 Pa?A?95×104 Pa  (1)
8×104 Pa?B?11×104 Pa  (2)
2×104 Pa?C?5×104 Pa  (3)
wherein, in the condition (1), A is a storage modulus of the pressure-sensitive adhesive composition after curing as measured at a temperature of ?20° C., an angular frequency of 6.28 rad/s, and a strain of 1%,
in the condition (2), B is a storage modulus of the pressure-sensitive adhesive composition after curing as measured at a temperature of 25° C., an angular frequency of 6.28 rad/s, and a strain of 1%, and
in the condition (3), C is a storage modulus of the pressure-sensitive adhesive composition after curing as measured at a temperature of 200° C., an angular frequency of 6.28 rad/s, and a strain of 1%.
US Pat. No. 11,027,014

METHODS USING GDF-15 ANTIBODIES FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

1. A method of treating pulmonary arterial hypertension (PAH) in a subject in need of treatment thereof, the method comprising administering a neutralizing antibody against Growth Differentiation Factor 15 (GDF-15) to the subject.
US Pat. No. 11,027,526

REFLECTIVE GLAZING COMPRISING A THIN LAYER OF SILICON-RICH SILICON NITRIDE

SAINT-GOBAIN GLASS FRANCE...

1. A glass article, comprising:a glass substrate on which a stack of layers is deposited,
wherein the stack comprises a layer comprising silicon nitride of a formulation SiNx, in which x is less than 1.25, as an SiNx layer,
wherein a physical thickness of the SiNx layer is in a range of from 5 to 50 nm,
wherein the glass article has a light reflection, measured on a side of the substrate on which the stack is deposited, greater than 35%, and
wherein the stack does not comprise a layer based on silver.
US Pat. No. 11,028,294

ACRYLATE-CYANOACRYLATE MONOMERS

International Business Ma...

1. A process of forming an acrylate-cyanoacrylate monomer, the process comprising:forming a mixture that includes a polyol, acrylic acid, and 2-cyanoacrylic acid; and
initiating a transesterification reaction to form an acrylate-cyanoacrylate monomer having at least one acrylate functional group and at least one cyanoacrylate functional group.
US Pat. No. 11,029,318

METHODS FOR PREDICTING AND TREATING PATIENTS WITH INCREASED RISK OF ADVERSE PREGNANCY OUTCOME

Kypha, Inc., St. Louis, ...

1. A method for treating a pregnant human at risk of an adverse pregnancy outcome comprising:(i) detecting in a first sample of blood or urine from the pregnant human a first level of iC3b, intact C3, and/or total C3 at a first time point during the first, second, or third trimester of pregnancy;
(ii) detecting in a second sample of blood or urine from the pregnant human a second level of iC3b, intact C3, and/or total C3 at a second time point during the third trimester of pregnancy;
(iii) comparing the first and second levels;
(iv) diagnosing the pregnant human as being at risk of an adverse pregnancy outcome by determining that the first and second levels are:
(a) iC3b and the second level is higher than the first level; and/or
(b) iC3b and intact C3 and the ratio of intact C3 to iC3b is the same as or lower than the first level; and/or
(c) total C3 and the second level is the same as or lower than the first level; and
(v) treating the pregnant human diagnosed as being at risk of an adverse pregnancy outcome with a treatment comprising administration of one or more of steroids, non-steroidal anti-inflammatory drugs (NSAIDs), hydroxychloroquine, chloroquine, quinacrine, methotrexate, azathioprine, cyclophosphamide, chlorambucil, cyclosporine, mycophenolate mofetil, rituximab, belimumab, complement inhibitors, plasmapheresis, delivery of the fetus, aspirin, one or more agents for treatment of hypertension, and/or one or more agents for treatment of eclamptic seizures.
US Pat. No. 11,027,015

ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS

Omeros Corporation, Seat...

1. An isolated antibody, or antigen-binding fragment thereof, that binds to human MASP-3 comprising:a heavy chain variable region comprising a HC-CDR1 set forth as SEQ ID NO:72 (SYGMS) a HC-CDR2 set forth as SEQ ID NO:74 (WINTYSGVPTYADDFKG); and a HC-CDR3 set forth as SEQ ID NO:76 (GGEAMDY); and a light chain variable region comprising a LC-CDR1 selected from the group consisting of SEQ ID NO:153 (KSSQSLLDSDGKTYLN), SEQ ID NO:261 (KSSQSLLDSEGKTYLN), SEQ ID NO:262 (KSSQSLLDSAGKTYLN) and SEQ ID NO:263 (KSSQSLLDSDAKTYLN); a LC-CDR2 set forth as SEQ ID NO:155 (LVSKLDS); and a LC-CDR3 set forth as SEQ ID NO:157 (WQGTHFPWT).
US Pat. No. 11,027,271

METHODS FOR PRODUCING MULTIFUNCTIONAL CATALYSTS FOR UPGRADING PYROLYSIS OIL

Saudi Arabian Oil Company...

1. A multifunctional catalyst produced by a method of making a multifunctional catalyst for upgrading pyrolysis oil, the method comprising:contacting a zeolite support with a solution comprising at least a first metal catalyst precursor and a second metal catalyst precursor, the first metal catalyst precursor, the second metal catalyst precursor, or both, comprising a heteropolyacid and the zeolite support comprising a molar ratio of silica to alumina of from 10 to 70, where the contacting deposits the first metal catalyst precursor and the second metal catalyst precursor onto outer surfaces and pore surfaces of the zeolite support to produce a multifunctional catalyst precursor;
removing excess solution from the multifunctional catalyst precursor; and
calcining the multifunctional catalyst precursor at a temperature of at least 500 degrees Celsius to produce the multifunctional catalyst comprising at least a first metal catalyst and a second metal catalyst deposited on the outer surfaces and pore surfaces of the zeolite support, and
where the multifunctional catalyst has an acidity of less than 10,000 micromoles of ammonia per gram (?mol(NH3)/g).
US Pat. No. 11,028,039

METHOD FOR PREPARING A ?-HYDROXYCARBOXYLIC ACID ESTER

Shenyang Gold Jyouki Tech...

1. A method for preparing a ?-hydroxycarboxylic acid ester, comprising the steps of:mixing an alkylene oxide, a monohydric alcohol, and a composite catalyst, and
performing a carbonylation esterification reaction in a carbon monoxide atmosphere to obtain the ?-hydroxycarboxylic acid ester;
wherein the composite catalyst comprises a main catalyst, a cocatalyst, and a reducing agent;
the main catalyst comprises at least one of a cobalt salt and a cobalt hydroxide;
the cocatalyst is a nitrogen-containing heterocyclic compound; and
the reducing agent is a base metal wherein the cobalt salt is selected from the group consisting of cobalt fluoride, cobalt chloride, cobalt bromide, cobalt iodide, cobalt acetate, cobalt carbonate, cobalt nitrate, cobalt sulfate, and combinations thereof;
wherein the nitrogen-containing heterocyclic compound is selected from the group consisting of a pyrazole compound, an imidazole compound, a pyridine compound, and a quinolone compound;
and wherein the base metal is selected from the group consisting of iron, zinc, manganese, nickel copper, and aluminum.
US Pat. No. 11,028,295

WOOD ADHESIVE FORMULATION

HUNTSMAN INTERNATIONAL LL...

1. A lignocellulosic body consisting of:(i) a plurality of lignocellulosic materials,
(ii) a two component adhesive formulation applied onto the lignocellulosic materials for bonding the lignocellulosic materials, the two component adhesive formulation consisting of:
(a) a first adhesive component which is formed from at least one isocyanate selected from hexamethylene diisocyanate, m-phenylene diisocyanate, p-phenylene diisocyanate, tolylene-2,4-diisocyanate, tolylene-2,6-diisocyanate, polymeric MDI, chlorophenylene-2,4-diisocyanate, naphthylene-1,5-diisocyanate, diphenylene-4,4?-diisocyanate, 4,4?-diisocyanate-3,3?-dimethyl-diphenyl, 3-methyl-diphenylmethane-4,4?-diisocyanate, diphenyl ether diisocyanate, cyclohexane-2,4-diisocyanate, cyclohexane-2,3-diisocyanate, 1-methylcyclohexyl-2,4-diisocyanate, 1-methylcyclohexyl-2,6-diisocyanate, bis-(isocyana-tocyclohexyl)methane, 2,4,6-triisocyanatotoluene, 2,4,4-triisocyanatodiphenylether, isophorone diisocyanate, butylene diisocyanate, trimethylhexamethylene diisocyanate, isocyanatomethyl-1,8-octane diisocyanate, tetramethylxylene diisocyanate, 1,4-cyclohexanediisocyanate, tolidine diisocyanate, and a mixture thereof and 64% by weight to 95% by weight, based on 100% by weight of the formulation of at least one amino resin, wherein said amino resin is the condensation product of an aldehyde with a compound selected from the group comprising urea, melamine, benzoguanamine, glycoluril, acetoguanamine and mixtures thereof; and
(b) a second adhesive component comprising at least one polyether compound, acting as a compatibilizing agent, having an average molecular weight of from 3500 to 40000 and an average nominal functionality of 2 to 6, wherein said polyether compound comprises at least 15% by weight ethylene oxide groups based on 100% by weight of the at least one polyether compound and at least one ethylene oxide moiety and at least two isocyanate reactive groups selected from the group consisting of hydroxyl, amino, epoxy, and thiol, and wherein the polyether compound is a reaction product of ethylene oxide and a polyfunctional initiator and, optionally, at least one other cyclic oxide; and wherein the ethylene oxide content to isocyanate is of at least 10% by weight based on the combined weight of the at least one isocyanate and the at least one polyether; and
(iii) optionally, an additive selected from the group comprising a hardener, a surfactant, a release agent, a wax, or a pigment.
US Pat. No. 11,029,319

BIOSENSOR AND APPLICATION OF THE SAME

NATIONAL CHENG KUNG UNIVE...

1. A biosensor, comprising:a substrate, wherein the substrate comprises a first region and a second region adjoined to the first region, the second region is located on one side of the first region, a center of the substrate is concentrically surrounded by the first region and the second region in order from outside to inside, a bottom of the first region has a recessed cross section having a first depth, a bottom of the second region has a recessed cross section having an asymmetric U-shape and a second depth, the second depth is greater than the first depth, and a slope of a side wall of the recessed cross section of the second region near the center is greater than a slope of another other side wall of the recessed cross section of the second region near the first region;
a first polymer layer, disposed in the first region, wherein a plurality of composite antibodies are distributed in the first polymer layer, and each of the composite antibodies comprises a labelling molecule and a first antibody connected to the labelling molecule; and
a second polymer layer, disposed in the second region, wherein the second polymer layer has an inverse opal photonic crystal structure, the inverse opal photonic crystal structure comprises a plurality of holes, a plurality of gold nanoparticles and a plurality of second antibodies are disposed on a wall of each of the holes, and the first antibody and the second antibodies recognize the same antigen.
US Pat. No. 11,027,016

PHARMACEUTICAL PREPARATION STABLY COMPRISING CD147 MONOCLONAL ANTIBODY

Xiaochun Chen, Jiangsu (...

1. A pharmaceutical formulation, comprising a CD147 monoclonal antibody, a buffer, a protein protective agent and a surfactant, wherein the buffer is histidine buffer, the protein protective agent is sucrose, and the surfactant is polysorbate 80, wherein the concentration of the histidine buffer is 9-11 mmol/L, the concentration of the sucrose in the pharmaceutical formulation is 80-110 mg/ml, and the concentration of the polysorbate 80 in the pharmaceutical formulation is 0.35-0.45 mg/ml.
US Pat. No. 11,028,040

METHODS FOR PRODUCING (METH)ACRYLIC ACID NORBORNYL ESTERS

BASF SE, Ludwigshafen am...

1. A method for preparing norbornyl (meth)acrylate by reacting norbornene with (meth)acrylic acid in the presence of boron trifluoride as catalyst, whereina) boron trifluoride is initially charged in (meth)acrylic acid,
b) the initial charge is heated to a temperature of 75 to 110° C.,
c) norbornene is added and
d) the norbornyl (meth)acrylate obtained is isolated from the reaction mixture.
US Pat. No. 11,027,017

PCI METHOD FOR GENERATING IMMUNE RESPOSE TO ANTIGENIC MOLECULE USING CHECKPOINT INHIBITOR AND TLR3 LIGAND

PCI Biotech AS, Oslo (NO...

1. A method of generating an immune response in a subject, comprising administering to a subject an antigenic molecule, a photosensitizing agent, a checkpoint inhibitor and a TLR3 ligand, and irradiating said subject with light of a wavelength effective to activate said photosensitizing agent, wherein an immune response is thereby generated, whereinthe antigenic molecule is a peptide,
the checkpoint inhibitor is an anti-CTLA4 antibody, an anti-PD-1 antibody, or both an anti-CTLA4 antibody and an anti-PD-1 antibody, and
the TLR3 ligand is a double stranded RNA molecule.
US Pat. No. 11,027,273

APPARATUSES AND METHODS FOR PATHOGEN DETECTION USING MICROFLUIDIC BIOCHIPS

BOARD OF REGENTS, THE UNI...

1. A hybrid microfluidic microplate apparatus comprising:a top layer comprising at least one inlet reservoir coupled to a microchannel,
a middle layer positioned beneath the top layer, said middle layer comprises at least one funnel shaped well comprising an upper well portion having a first diameter of 1 mm (millimeter) to 5 mm and a lower well portion having a second diameter of 0.1 mm to 1 mm, wherein a top portion of the upper well portion is connected to the microchannel in the top layer, and a bottom portion of the upper well portion is connected to a top portion of the lower well portion through a junction, and the second diameter is smaller than the first diameter,
an insert positioned inside the upper well portion and over the junction of the upper well portion and the lower well portion, said insert forms a separate layer within the at least one funnel shaped well and is made of a first material comprising a porous paper comprising cellulose, nitrocellulose, nylon, or any combinations thereof, and
a bottom layer positioned beneath the middle layer, said bottom layer comprises an outlet hole coupled to at least one outlet channel, said at least one outlet channel is coupled to a bottom portion of the lower well portion, and the outlet hole is fluidly connected to the inlet reservoir via the microchannel in the top layer, upper well portion, lower well portion, and at least one outlet channel,
wherein the top layer, the middle layer and the bottom layer is made with a second material comprising a polymer.
US Pat. No. 11,029,321

METHOD OF EVALUATING CORPUS LUTEUM FUNCTION BY RECURRENTLY EVALUATING PROGESTERONE NON-SERUM BODILY FLUIDS ON MULTIPLE DAYS

MFB Fertility, Inc., Eri...

2. A method for evaluating a series of samples of a non-serum bodily fluid sample of a subject, each sample of the series collected daily during a period of at least three and not more than four consecutive days during the timeframe of 7-10 days past the ovulation date, to evaluate corpus luteum function by estimating the levels of progesterone, comprising:predicting the timeframe of 7-10 days past the ovulation date to optimally conduct testing for progesterone or a progesterone metabolite by a step selected from the group consisting of:
a. testing urine with a lateral flow assay test configured to evaluate urine for the presence of luteinizing hormone to determine the ovulation date;
b. measuring a rise in basal body temperature of at least 0.5 degrees Fahrenheit to determine the ovulation date;
c. utilizing a menstrual cycle tracking application operating on a mobile device configured to determine the ovulation date; and
d. sampling cervical mucus to determine the ovulation date,
collecting a non-serum bodily fluid sample daily for at least three and not more than four consecutive days during the timeframe of 7-10 days past the ovulation date;
for each fluid sample collected on each of the consecutive days, testing for the presence of progesterone or a metabolite of progesterone by a step selected from the group consisting of:
a. evaluating urine with a specially configured lateral flow assay, the specially configured lateral flow assay comprising:
a sample pad configured to receive each urine sample,
a receiving zone within a conjugate pad, the conjugate pad saturated with a conjugate of an anti-PdG antibody conjugated to a visual label at a concentration of 1-10 ?g/ml, and
a membrane comprising a testing zone,
the testing zone comprising a PdG conjugated to a carrier protein that binds PdG antigens at 8-32 molecules per carrier protein and configured to evaluate for the presence or absence of PdG at or above a PdG threshold, the PdG threshold selected from within the range inclusive of 3-20 ?g/ml, and
an adsorbent pad at an end of the specially configured lateral flow assay opposite from the sample pad;
b. evaluating a saliva sample with the aid of a diagnostic test system, the diagnostic test system comprising:
an assay device comprising at least one testing region configured to evaluate an applied saliva sample for the presence of progesterone or a progesterone analyte,
a port for receiving an assay device,
a reader comprising one or more light sources for illuminating the testing region,
a data analyzer configured to receive optical signals and determine an amount of an analyte present in the saliva sample, and transmit a result as an output; and
evaluating saliva with a lateral flow test device for quantitatively detecting an analyte in a saliva sample configured to quantitatively detect progesterone at or above a threshold value selected from the range of 90-300 pg/ml;
observing the result for the presence of progesterone or a metabolite of progesterone;
following the first result indicating the presence of progesterone or a metabolite of progesterone above the PdG threshold in the tested non-serum bodily fluid sample or the first fold change, repeating the collecting step and the testing step for three days or until the first result indicating progesterone or a metabolite of progesterone is below the PdG threshold; and
recording the total number of days the presence of progesterone is indicated or a metabolite of progesterone is indicated above the PdG threshold during the timeframe of 7-10 days past the ovulation date, or the total number of days the presence of progesterone is indicated or a metabolite of progesterone is indicated above the PdG threshold prior to the first result indicating progesterone is absent or a metabolite of progesterone is below the PdG threshold.
US Pat. No. 11,027,018

USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS

The University of Iowa Re...

1. A method of inhibiting, preventing or treating diarrhea in a subject comprising elevated levels of CGRP, wherein said elevated CGRP levels are associated with an acute condition comprising administering an effective amount of an anti-CGRP antibody or anti-CGRP antibody fragment, wherein the anti-CGRP antibody or antibody fragment comprises a variable light (VL) chain comprising the complementarity determining region (“CDR”) 1 sequence of SEQ ID NO: 25, the CDR2 sequence of SEQ ID NO: 26, and the CDR3 sequence of SEQ ID NO: 27, and a variable heavy (VH) chain comprising the CDR1 sequence of SEQ ID NO: 28, the CDR2 sequence of SEQ ID NO: 29, and the CDR3 sequence of SEQ ID NO: 30.
US Pat. No. 11,028,042

PROCESS FOR PREPARING AN AROMATIC POLYAMINE MIXTURE

BASF SE

1. A process for preparing an aromatic polyamine mixture comprising 4,4?-methylenedi(phenylamine) and higher homologues of methylenedi(phenylamine), the process comprising(i) reacting aniline with formaldehyde in the presence of an acid catalyst to form a crude product mixture (I) in a plant which comprises a mixing zone (a), a condensation zone (b), a rearrangement zone (c) and optionally an after-reaction zone (d);
(ii) neutralizing the crude product mixture (I) obtained in (i) and removing salts thus formed, to obtain a crude product mixture (II);
(iii) separating aniline from the crude product mixture (II) obtained in (ii), to obtain separated aniline and a crude product mixture (III), and optionally recirculating the separated aniline to the mixing zone (a); then
(iv) distilling the crude product mixture (III) obtained in (iii) wherein the distilling comprises
(iv-1) isolating a mixture (II) consisting of methylenedi(phenylamine) isomers (II-1) and secondary components (II-2) which are different therefrom, where, based on (II-1), a proportion of 4,4?-methylenedi(phenylamine) is from 8 to 20% by weight and, based on (II), a proportion of secondary components (II-2) is not more than 0.3% by weight, and
(iv-2) isolating a low boiler mixture which consists of secondary components (II-2) and methylenedi(phenylamine) isomers (II-1) and in which a proportion of the secondary components (II-2) is at least 55% by weight; and
(v) recirculating the mixture (II) to one of the zones (a) to (d),
wherein the aromatic polyamine mixture has a content of 4,4?-methylenedi(phenylamine) and higher homologues of methylenedi(phenylamine) of greater than 85% by weight.
US Pat. No. 11,027,020

DELIVERY CONSTRUCTS FOR TRANSCYTOSIS AND RELATED METHODS

Applied Molecular Transpo...

1. A delivery construct comprising a carrier coupled to a payload, wherein the delivery construct has at least 90% sequence identity to SEQ ID NO: 17, and wherein the carrier consists of the amino acid sequence set forth in SEQ ID NO: 7 or SEQ ID NO: 9, or an amino acid sequence having at least 95% sequence identity thereto.
US Pat. No. 11,027,532

LAMINATE

LG Chem, Ltd.

1. A method for manufacturing a laminate, the laminate comprising a substrate and a polymer film, the method comprising:coating a coating liquid on a substrate at a coating speed of 10 mm/sec to 100 mm/sec using a coating means;
annealing the coating liquid to form a polymer film,
wherein the coating liquid comprising a block copolymer dissolved in a solvent having a boiling point in a range of 90° C. to 200° C.,
wherein the coating speed is a moving speed of the substrate relative to the coating means, or a moving speed of the coating means relative to the substrate, and
wherein the coating of the coating liquid is performed by a bar coating method.
US Pat. No. 11,027,533

METHOD FOR PRODUCING LAMINATED BODY, LAMINATED BODY AND PAPER PACKAGING MATERIAL

TOPPAN PRINTING CO., LTD....

5. A laminated body comprising:a base material composed of at least acid-resistant paper; and
a coating layer containing cellulose nanofibers and laminated on the base material; wherein
an average fiber diameter of the cellulose nanofibers is 2 nm or more and 2000 nm or less,
a content of the cellulose nanofibers in the coating layer is 10 mass % or more of the coating layer,
a coating amount of the coating layer is 0.2 g/m2 or more in dry mass,
an arithmetic average surface roughness of a surface of the coating layer is 1.1 ?m or less, and an adhesion strength between the base material and the coating layer is 1.0 N/15 mm or more, and
the cellulose nanofibers includes:
first cellulose nanofibers resulted from fibrillating non-chemically treated cellulose raw material, and
second cellulose nanofibers having a different chemical structure from a chemical structure of the first cellulose nanofibers, the second cellulose nanofibers having carboxyl groups substituted for hydroxyl groups resulted from oxidation based on a 2,2,6,6-tetramethyl-1-piperidine-N-oxy radical.
US Pat. No. 11,028,045

PROCESS FOR REDUCING CPI IN A DINITRILE STREAM

INV NYLON CHEMICALS AMERI...

1. A process for removing at least a portion of CPI from a mixture comprising CPI and at least one dinitrile, said process comprising reacting CPI in the mixture with an amine, wherein the amine is an aliphatic or aromatic amine.
US Pat. No. 11,028,301

TEMPERATURE REGULATING POLYURETHANE GELS

TECHNOGEL ITALIA S.R.L., ...

1. A temperature regulating polyurethane gel composition, comprising a non-exuding phase change material (PCM), selected from the group consisting of fatty acid esters and mixtures thereof, directly incorporated within a polyol dispersing phase of a polyurethane gel composition, wherein the temperature regulating polyurethane gel composition has a phase change temperature, that is both the melting temperature and the crystallisation temperature, that ranges from ?20° C. to +50° C. and wherein a fluid expanding a gel network is provided by the polyol component which comprises one or more long chain polyether polyols,wherein the isocyanate component comprises one or more isocyanates with a reactive functionality from 1.5 to 3.5,
wherein the PCM is directly incorporated into a fluid phase of the polyurethane gel without encapsulation,
wherein the one or more long chain polyether polyols is an alkylene oxide polyether polyol produced by the addition of alkylene epoxide to a starting component comprising reactive hydrogen, selected from the group consisting of a propylene oxide polyether polyol with a number average molecular weight above 1900 and a propylene oxide/ethylene oxide polyether polyol with up to 25 wt. % of ethylene oxide (EO) and with a number average molecular weight above 1900,
wherein the PCM is selected from the group consisting of fatty acid monoesters and mixtures thereof,
wherein a single phase polyol component PCM mixture with complete miscibility between the polyol component and the PCM without phase separation.
US Pat. No. 11,031,632

METHOD FOR RECOVERING POSITIVE ELECTRODE ACTIVE MATERIAL FROM LITHIUM SECONDARY BATTERY

LG Chem, Ltd.

1. A method for recovering a positive electrode active material from a lithium secondary battery, the method comprising:1) separating a positive electrode into a collector and a positive electrode part;
2) removing an organic substance by firing the separated positive electrode part;
3) washing the fired resultant and removing residual fluorine (F); and
4) adding a lithium-containing material into the washed resultant and firing to reform a lithium transition metal oxide,
wherein the washing of step 3) is performed by using pure water.
US Pat. No. 11,027,023

NATURAL TYPE MIRNA FOR CONTROLLING GENE EXPRESSION, AND USE OF SAME

BONAC CORPORATION, Kurum...

1. A single-stranded nucleic acid comprising X region and Y region,wherein
the 3?-terminus of said X region and the 5?-terminus of said Y region are linked via a linker region of a non-nucleotide structure,
said X region comprises (a) a guide strand sequence or (b) a passenger strand sequence of a mature miRNA,
when the X region comprises (a), said Y region comprises a passenger strand sequence of said mature miRNA,
when the X region comprises (b), said Y region comprises a guide strand sequence of said mature miRNA,
said X region further comprises an additional sequence of 3-5 base length, and
said guide strand sequence and said passenger strand sequence form a double-stranded structure.
US Pat. No. 11,028,047

METHOD FOR RECOVERING DIMETHYL SULFOXIDE FROM RECOVERED RESIST REMOVER

KURARAY CO., LTD., Kuras...

1. A method for recovering dimethyl sulfoxide from a composition, the method comprising:contacting the composition with water, where the composition comprises at least one compound selected from a group consisting of glycol ethers, glycols, and triols, and dimethyl sulfoxide;
and performing distillation on the composition contacted with water to recover a purified dimethyl sulfoxide product,
wherein an amount of the water contacted with the composition is from 0.1 to 100 parts by mass with respect to 1 part by mass of the composition.
US Pat. No. 11,028,303

SODIUM-TIN AND SODIUM-TIN-LEAD COOLANTS

TerraPower, LLC, Bellevu...

1. A composition consisting of:94.5-95.5 mol % Na;
2.5-3.5 mol % Pb; and
the balance being Sn.
US Pat. No. 11,027,024

METHODS OF DELIVERY OF TRANSGENES FOR TREATING BRAIN DISEASES

UNIVERSITY OF IOWA RESEAR...

1. A method of delivering a therapeutic agent to a central nervous system (CNS) cell of a mammal, wherein the mammal exhibits Spinocerebellar Ataxia Type 1 (SCA1) disease, comprising directly injecting to the mammal's deep cerebella nuclei a recombinant adeno-associated virus (rAAV) particle comprising a nucleic acid encoding an AAV1 capsid protein and a nucleic acid encoding miRNA ataxin type 1 (Atxn1) inserted between a pair of AAV2 inverted terminal repeats in a manner effective to infect the CNS cell of the mammal such that the CNS cell expresses the therapeutic agent in the mammal, and wherein the therapeutic agent is the nucleic acid encoding the miRNA Atxn1, and wherein the rAAV particle comprises the nucleotide sequence as set forth in SEQ ID NO: 14 and the CNS cell is a cerebellar Purkinje cell or deep cerebella nuclei.
US Pat. No. 11,028,048

HETEROCYCLIC COMPOUND AND USE THEREOF

Takeda Pharmaceutical Com...

1. N?-{(2 S,3R,4S)-1-(azetidine-1-carbonyl)-4-fluoro-2-[(2-fluoro-3 methyl[1,1?-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}-N,N-dimethyl sulfuric diamide or a salt thereof.
US Pat. No. 11,027,025

COMPOSITIONS COMPRISING SYNTHETIC POLYNUCLEOTIDES ENCODING CRISPR RELATED PROTEINS AND SYNTHETIC SGRNAS AND METHODS OF USE

ModernaTX, Inc., Cambrid...

1. A composition comprising(i) a plurality of lipid nanoparticles comprising a biodegradable cationic lipid, a non-cationic lipid, a sterol, and a PEG-lipid;
(ii) mRNA comprising:
(a) a first region of linked nucleosides consisting of nucleotides selected from 1-methyl-pseudouridine, cytidine, adenosine, and guanosine and encoding a protein comprising the sequence of SEQ ID NO: 7, 8, 9, 61, 62, 63, 64, or 65;
(b) a 5?-untranslated region (UTR); and
(c) a 3?-UTR comprising the sequence of SEQ ID NO: 81; and
(iii) sgRNA comprising:
(a) a first region of linked nucleosides complementary to either strand of a 5? UTR of a gene of interest;
(b) a second region comprising a guide RNA scaffold sequence located at the 3? terminus of the first region; and
(c) at least one phosphorothioate linkage and at least one nucleotide with a modification at the 2?-position of the sugar,
wherein the plurality of lipid nanoparticles encapsulate the mRNA and/or the sgRNA.
US Pat. No. 11,028,049

ELECTRON DONOR, AND METHOD FOR SYNTHESIZING 4, 4?-BIPYRIDINE USING ELECTRON DONOR

Kobelco Eco-Solutions Co....

1. An electron donor comprising a mixture of a dispersion product obtained by dispersing sodium metal or sodium metal alloy in a dispersion solvent, and 1,3-dimethyl-2-imidazolidinone and wherein a lower layer of the mixture that has been divided into two layers is used as the electron donor.
US Pat. No. 11,027,282

DIGITAL TO BIOLOGICAL CONVERTER

Codex DNA, Inc., San Die...

1. An automated system for the synthesis of a double-stranded DNA molecule according to provided biological sequence information, comprising:an assembly unit that assembles the double-stranded DNA molecule according to the provided biological sequence information, the assembly unit comprising or connected to vessels containing a plurality of oligonucleotide molecules and containing components that transport reagents within the system and that executes steps in an automated method for synthesizing the double-stranded DNA molecule, wherein the method comprises the assembly of one or more dsDNA molecule(s) by joining the plurality of oligonucleotides, and wherein no human intervention occurs after the method is initiated and until the double-stranded DNA molecule is synthesized;
and the system further comprising a non-transitory computer readable medium containing software programming instructions that direct steps in the assembly unit for the assembly of the plurality of oligonucleotide molecules into the double stranded DNA molecule in the automated method,
wherein the software programming instructions direct a step of PCR amplification in a first reaction zone of a reaction container, a step of error correction in a second reaction zone of a reaction container performed after the step of PCR amplification, a step of DNA assembly in a third reaction zone of a reaction container, and directs the transport of reagents from one reaction zone to the next, wherein the reaction container is a reaction plate having dimensions of about 127 mm× about 85 mm, and the reaction zones comprise one or more reaction wells on the reaction plate; and
wherein the system further comprises a robotic arm configured to transfer the oligonucleotide molecules from the first reaction zone to the second reaction zone, and from the second reaction zone to the third reaction zone, the sample successively accumulating in each reaction zone.
US Pat. No. 11,028,050

SALTS AND POLYMORPHS OF A PDE4 INHIBITOR

TETRA DISCOVERY PARTNERS,...

1. A crystalline form of free base Compound 1 (Form A), characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 12.72, 15.90, 19.39, 20.80, 20.98, 23.15, and 26.08,±0.2° 2? using Cu K? radiation.
US Pat. No. 11,028,307

MODIFIED CELLULOSE NANOCRYSTALS AND THEIR USE IN DRILLING FLUIDS

Board of Supervisors of L...

1. A drilling fluid comprising an aqueous suspension of clay particles, sodium hydroxide for pH control, lignite as a deflocculant, polyanionic cellulose as a solid control agent, a finely-ground calcium montmorillonite clay/silica mixture as a viscosifier, and a composition comprising 0.01% to 5% of said drilling fluid by mass; wherein:(a) said composition comprises nanocellulose covalently bonded to first and second polymers;
(b) said nanocellulose comprises cellulose particles 1 ?m or less in length, and 100 nm or less in diameter;
(c) said first polymer is negatively charged at pH 7.5-10; and
(d) said second polymer is positively charged at pH 7.5-10.
US Pat. No. 11,028,308

INVERT EMULSIFIERS FROM DCPD COPOLYMERS AND THEIR DERIVATIVES FOR DRILLING APPLICATIONS

SCHLUMBERGER TECHNOLOGY C...

12. A method of drilling, comprising:pumping a wellbore fluid into a wellbore through an earthen formation, the wellbore fluid comprising:
an oleaginous continuous phase;
a non-oleaginous discontinuous phase formed as emulsion droplets; and
a polymer having a polycyclic backbone and a polydispersity ranging from 1.77 to 2.48,
wherein
a particle size distribution of a majority of the emulsion droplets is less than 100 microns
a first portion of the emulsion droplets having first particle sizes of less than 10 microns, and
a second portion of the emulsion droplets have second particle sizes of greater than 10 microns and less than 100 microns.
US Pat. No. 11,027,030

KIT FOR RADIOLABELLING

1. A radiolabelling kit comprising:a first vial, wherein said first vial is empty and under vacuum;
a second vial, wherein said second vial comprises a suitable amount of acetate buffer for balancing the pH of an eluate from a gallium-68 generator to a pH value ranging from 3 to 5 when said eluate is eluted into the kit; and
a third vial, wherein said third vial comprises a lyophilized chelate-functionalized targeting agent and a lyophilized metal inhibitor,
wherein the chelator group of said chelate-functionalized targeting agent is selected from the group consisting of: NOTA, NODAGA, Tris(hydroxypyridinone) (THP), HBED, DFO 6SS, B6SS, PLED, YM103, and H2dedpa; and
wherein said metal inhibitor is selected from the group consisting of: DOTA, tetra-tBu-DTPA, beta-cyclodextrin and a monosacccharide.
US Pat. No. 11,027,031

KIT FOR RADIOLABELLING

1. A method for radiolabelling a chelate-functionalized targeting agent with gallium-68, comprisingrecovering an eluate of a gallium-68 generator into a first vial located within a self-shielded device;
adding a suitable amount of acetate buffer to a second vial comprising a lyophilized chelate-functionalized targeting agent and a lyophilized metal inhibitor to form a mixture comprising acetate buffer, chelate-functionalized targeting agent and metal inhibitor, wherein the acetate buffer is added in a suitable amount to balance the pH of the eluate from the gallium-68 generator to a pH value ranging from 3 to 5 when the mixture is contacted with the eluate;
recovering the mixture of acetate buffer, chelate-functionalized targeting agent and metal inhibitor from the second vial;
adding the mixture of acetate buffer, chelate-functionalized targeting agent and metal inhibitor to the recovered eluate of the gallium-68 generator in the first vial located within the shielding device; and
allowing radiolabelling of the chelate-functionalized targeting agent with gallium-68,
wherein said metal inhibitor is selected from the group consisting of: DOTA, glucose, fructose, beta-cyclodextrin, D-mannose, and tetra-tBu-DTPA, and
wherein said chelator in said chelate-functionalized targeting agent is selected from the group consisting of: NOTA, NODAGA, HBED and DFO.
US Pat. No. 11,028,311

METHODS OF CEMENTING A WELLBORE

BAKER HUGHES OILFIELD OPE...

1. A method of cementing a wellbore, the method comprising:combining an alginate suspension additive with a cement slurry to form a cement composition, the cement slurry comprising about 10 wt. % to about 60 wt. % of an aqueous carrier and about 60 wt. % to about 90 wt. % of a cementitious component, each based on the total weight of the cement slurry;
injecting the cement composition into the wellbore; and
allowing the cement composition to set,
wherein the alginate suspension additive is added in an amount of about 0.01 wt. % to about 5 wt. % based on the weight of the aqueous carrier in the cement slurry.
US Pat. No. 11,028,057

PROCESS FOR THE SYNTHESIS OF 6-CHLOROMETHYLURACIL

Procos S.P.A., Cameri (I...

1. A process for the preparation of 6-chloromethyluracil comprising the following steps:a) reacting ethyl 4-chloroacetoacetate and S-methylisothiourea hemisulfate to yield the isolated intermediate 6-(chloromethyl)-6-hydroxy-2-(methylthio)-5,6-dihydropyrimidin-4(1H)-one;
b) reacting said 6-(chloromethyl)-6-hydroxy-2-(methylthio)-5,6-dihydropyrimidin-4(1H)-one with aqueous sulfuric acid to yield 6-chloromethyluracil.
US Pat. No. 11,028,314

COMPOSITIONS COMPRISING AMINATED DEXTRIN COMPOUNDS AND SUBTERRANEAN TREATMENT METHODS USING THE SAME

Integrity Bio-Chemicals, ...

13. A method comprising:providing a clay stabilizing composition comprising:
an amine-functionalized dextrin compound, the amine-functionalized dextrin compound comprising 2 to about 20 glucose units linked together with ?(1,4) glycosidic bonds, and a portion of the glucose units being oxidatively opened and functionalized with at least one amine group at a site of oxidative opening, and
an amine-functionalized dextran polymer, the amine-functionalized dextran polymer comprising a plurality of glucose units linked together with ?(1,6) glycosidic bonds, and a portion of the glucose units being oxidatively opened and functionalized with at least one amine group at a site of oxidative opening;
introducing the clay stabilizing composition into a subterranean formation bearing a clay-containing mineral; and
interacting the amine-functionalized dextrin compound and the amine-functionalized dextran polymer with the clay-containing mineral to affect stabilization thereof;
wherein the amine-functionalized dextrin compound and the amine-functionalized dextran polymer operate synergistically with one another when interacting with the clay-containing mineral, such that the clay stabilizing composition is more effective for clay stabilization than is an equal amount of either the amine-functionalized dextrin compound or the amine-functionalized dextran polymer.
US Pat. No. 11,029,595

MASK ASSEMBLY AND ASSOCIATED METHODS

ASML Netherlands B.V., V...

1. A mask assembly container comprising an opening through which a mask assembly may be placed inside the container, and a seal that seals shut the opening when the mask assembly is located inside the container, wherein the container has a floor configured to accommodate outward sagging of a pellicle.
US Pat. No. 11,028,060

CRYSTALLINE FORMS OF OZANIMOD AND PROCESSES FOR PREPARATION THEREOF

RECEPTOS LLC, New York, ...

1. A crystalline form CS10 of ozanimod, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 5.7°±0.2°, 25.0°±0.2° and 26.6°±0.2° using CuK? radiation.
US Pat. No. 11,028,317

ADDITIVES FOR ELIMINATING FRACTURING FLUIDS USED FOR OIL EXTRACTION

RHODIA OPERATIONS, Auber...

11. A method, comprising using, as a flowback aid, at least one surfactant, in which the at least one surfactant comprises a mixture of a surfactant of sulfonate type with an anionic surfactant of alkoxylated alkyl sulfate type, in an aqueous fracturing fluid, which is capable of lowering the interfacial tension of the aqueous fracturing fluid with decane and/or hexadecane below 0.1 mN/m.
US Pat. No. 11,028,062

CATALYTIC HYDROLYSIS AND DEHYDRATION OF SACCHARIDES

THE BOARD OF TRUSTEES OF ...

1. A method of producing hydroxymethylfurfural (HMF) and levulinic acid comprising:providing a saccharide feedstock including glucose;
bringing the saccharide feedstock into contact with a solid state catalytic structure at a first temperature sufficient to effectuate dehydration of the glucose to provide the HMF; and
bringing the HMF into contact with the solid state catalytic structure at a second temperature sufficient to produce levulinic acid,
wherein the solid state catalytic structure comprises a substrate having one or more surfaces functionalized with saccharide solubilization functionalities and acid functionalities,
wherein the saccharide solubilization functionalities comprise one or more imidazolium halide salts pendant along chains of a first polymeric species attached to the substrate surface, and the acid functionalities are pendant along chains of a second polymeric species attached to the substrate surface, and
wherein the second temperature is higher than the first temperature, wherein the substrate is functionalized according to the reaction scheme of FIG. 1.
US Pat. No. 11,027,039

ABSORBENT MATERIAL, AND SYSTEM AND METHOD OF MAKING SAME

DSG Technology Holdings L...

1. A method of forming fiber-SAP particles, comprising mixing fibers with superabsorbent particles (SAP) such that at least some of the fibers attach to at least some of the SAP, thereby forming fiber-SAP particles, wherein said mixing is preceded by providing wetted fibers and introducing said wetted fibers with said SAP, and each fiber-SAP particle comprises a plurality of the fibers attached to one of the superabsorbent particles.
US Pat. No. 11,028,320

ALUMINATE FLUORESCENT MATERIAL, LIGHT EMITTING DEVICE USING THE SAME, AND METHOD OF PRODUCING ALUMINATE FLUORESCENT MATERIAL

NICHIA CORPORATION, Anan...

1. A method of producing an aluminate fluorescent material, comprising:mixing compounds that contain elements to provide a composition containing a first element that contains one or more elements selected from Ba and Sr, a second element that contains Mg and Mn, and Al and O to obtain a raw material mixture, and
heat-treating the raw material mixture, wherein:
in the composition, when a molar ratio of Al is taken as 10, a total molar ratio of the first element is a value of a parameter a, a total molar ratio of the second element is a value of a parameter b, a molar ratio of Sr is a product of a value of a parameter m and the value of the parameter a, a molar ratio of Mn is a product of a value of a parameter n and the value of the parameter b, and
the values of the parameters a and b satisfy the following requirement (1), the value of the parameter m satisfies the following requirement (2), and the value of the parameter n satisfies the following requirement (3):
0.7 0?m?1.0  (2)
wherein the value of the parameter n satisfies 0.6?n<0.7, or the product of the value of the parameter b and the value of the parameter n (b×n) is a value satisfying 0.3
US Pat. No. 11,029,601

POSITIVE TONE PHOTOPATTERNABLE SILICONE

Dow Silicones Corporation...

6. A composition comprising (i) a polysiloxane comprising alkenyl groups, (ii) a silane crosslinker comprising silicon-hydrogen bonds, (iii) a hydrosilylation catalyst, and (iv) a photolatent amine generator; wherein the composition comprises no more than 0.1 wt % siloxane units having epoxy groups based on weight of composition solids; wherein the polysiloxane comprising alkenyl groups comprises from 0.5 to 20 wt % alkenyl groups; and wherein the polysiloxane comprising alkenyl groups is (A) an alkenyl-terminated polysiloxane that comprises units of R1R2SiO2/2 and alkenyl end groups, wherein R1 and R2 independently represent C1-C20 substituted or unsubstituted hydrocarbyl groups, (B) a vinyl-substituted MQ resin; or (C) a combination thereof; and wherein the silane crosslinker is a compound having at least three silicon-hydrogen bonds or a polymer having from 0.01 to 2.0 wt % SiH.
US Pat. No. 11,028,322

COMPOSITION FOR WASHING PICKLED STEEL PLATE, METHOD FOR WASHING PICKLED STEEL PLATE BY USING SAME, AND STEEL PLATE OBTAINED THEREBY

POSCO, Pohang-si (KR)

1. A composition for washing a pickled steel plate comprising 6 to 14 wt % of a phosphoric acid ester compound, 6 to 19 wt % of an amine-based compound, 1 to 9 wt % of sodium carbonate, 1 to 9 wt % of ammonium acetate, 1 to 14 wt % of ethylene diamine tetraacetic acid (EDTA), and a remainder of water; with the proviso that the amine-based compound is not (EDTA).
US Pat. No. 11,028,323

LIQUID CRYSTAL ALIGNING AGENT CONTAINING CROSSLINKING AGENT AND POLYMER THAT HAS SITE HAVING ISOCYANATE GROUP AND/OR BLOCKED ISOCYANATE GROUP AND SITE HAVING PHOTOREACTIVITY, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT

NISSAN CHEMICAL INDUSTRIE...

1. A liquid crystal aligning agent comprising the following component (A), the following component (B), and an organic solvent:Component (A): a polymer comprising a (A-1) site having an isocyanate group and/or a blocked isocyanate group; and a (A-2) site having photoalignment;
Component (B): a compound comprising in a molecule of the compound two or more functional groups, each of which is at least one selected from the group consisting of an amino group and a hydroxyl group,
wherein the (A-1) site having an isocyanate group and/or a blocked isocyanate group is represented by following formula (1), wherein Ia represents an isocyanate group or a blocked isocyanate group,
Sa represents a spacer unit, the bonding pointer left of Sa represents bonding to the backbone of a polymer of the component (A) optionally via a spacer:
—Sa—Ia   (1),
wherein the (A-1) site having an isocyanate group and/or a blocked isocyanate group is derived from a monomer represented by the formula (1m),
Ma-Mb?Sa—Ia]c   (1m);
wherein Ma represents a first polymerizable group,
Mb represents a single bond, a divalent heterocycle, a trivalent heterocycle, a tetravalent heterocycle, a substituted or unsubstituted linear or branched alkyl group having a carbon number of 1 to 10, a divalent aromatic group, a trivalent aromatic group, a tetravalent aromatic ring, a divalent alicyclic group, a trivalent alicyclic group, a tetravalent alicyclic group, a divalent condensed cyclic group, a trivalent condensed cyclic group or a tetravalent condensed cyclic group, wherein each group may be unsubstituted, or one or more hydrogen atoms in each group may be substituted with a fluorine atom, a chlorine atom, a cyano group, a methyl group, or a methoxy group,
Sa represents a spacer unit,
Ia represents an isocyanate group or a blocked isocyanate group, and
c represents an integer of 1 to 3; and
wherein Sa in the formula (1) and/or the formula (1m) is represented by the formula (2):
—W1-A1-W2-A2-W3—  (2)
wherein the bonding left of W1 represents bonding to Mb,
the bonding right of W3 represents bonding to Ia,
W1, W2, and W3 each independently represents a single bond, a divalent heterocycle, —(CH2)n— wherein n represents 1 to 20, —OCH2—, —CH2O—, —COO—, —OCO—, —CH?CH—, —CF?CF—, —CF2O—, —OCF2—, —CF2CF2— or —C?C—, wherein one or more non-adjacent CH2 groups in these substituents may be independently substituted with —O—, —CO—, —CO—O—, —O—CO—, —Si(CH3)2—O—Si(CH3)2—, —NR—, —NR—CO—, —CO—NR—, —NR—CO—O—, —OCO—NR—, —NR—CO—NR—, —CH?CH—, —C?C— or —O—CO—O—, wherein R represents independently a hydrogen or a linear or branched alkyl group having a carbon number of 1 to 5,
A1 and A2 each independently represents a divalent aromatic group, a divalent alicyclic group, a divalent heterocyclic group, or a divalent condensed cyclic group, wherein each group may be unsubstituted, or one or more hydrogen atoms in each group may be substituted with a fluorine atom, a chlorine atom, a cyano group, a methyl group or a methoxy group.
US Pat. No. 11,031,654

HIGH-WETTABILITY SEPARATOR AND PREPARATION METHOD THEREOF

Shanghai Energy New Mater...

1. A lithium ion battery separator, wherein the separator consists of:an ethylene copolymer, a grafted polyolefin, an ultrahigh molecular weight polyethylene having a molecular weight of 3.5×106 to 10.0×106, and a high-density polyethylene having a density in the range of 0.940 to 0.976 g/cm3;
wherein the content of the ethylene copolymer is 1-5 parts by weight and the content of the grafted polyolefin is 1-5 parts by weight, on the basis that the total weight of the ultrahigh molecular weight polyethylene and the high-density polyethylene is 100 parts;
wherein the ethylene copolymer is one or more selected from the group consisting of ethylene-vinyl acetate copolymer, ethylene-acrylate copolymer, ethylene-acrylic acid copolymer, and ethylene-methyl methacrylate copolymer; and
wherein the grafted polyolefin is one or more selected from the group consisting of maleic anhydride grafted polyethylene, and glycidyl methacrylate grafted polyethylene.
US Pat. No. 11,027,045

SYNTHETIC NICHE MATRICES FOR STEM CELL CULTURE

POLITECNICO DI MILANO, M...

1. A supermatrix of synthetic niches comprising at least a first and a second matrix of synthetic niches,wherein each matrix comprises n×m synthetic niches, wherein n and m, the same or different from each other, independently have a value ?1, provided that one of m or n is ?2 and with a maximum value of m and n which allows to maintain a structure of a single synthetic niche intact such that shrinking or contraction of the synthetic niche does not cause a disruption or detachment of a niche matrix, and
wherein a distance (d) between each synthetic niche matrix and another is greater than zero and
wherein in each matrix every synthetic niche has one or more walls in common with at least one other synthetic niche of the matrix.
US Pat. No. 11,028,069

SALT OF SUBSTITUTED PIPERIDINE COMPOUND

TAIHO PHARMACEUTICAL CO.,...

1. A hydrochloride salt of 1-(2,3-dichlorobenzoyl)-4-((5-fluoro-6-(5-methyl-1H-pyrazol-3-ylamino)pyridin-2-yl)methyl)piperidine-4-carboxylic acid,wherein the salt is a crystal having characteristic peaks at at least 3 or more diffraction angles (2?±0.2°) selected from 12.83°, 13.54°, 16.20°, 18.27°, 23.80°, 29.10°, and 32.83° in powder X-ray diffraction spectrum.
US Pat. No. 11,027,048

METHODS FOR TISSUE DECELLULARIZATION

DECELL TECHNOLOGIES INC.,...

1. A bioprosthetic tissue, wherein the tissue is 95±5% free of nucleic acids, wherein the tissue is 95±5% free of major histocompatibility molecules, wherein the tissue is 95±5% free of Staphylococcus bacteria, Streptococcus bacteria, Enterococcus bacteria, and Bacillus bacteria, or complies with American Association of Tissue Banks Standards for Tissue Banking under K2.200, wherein the collagen structure of the tissue is not altered compared to a fresh control tissue as measured by a Hydrothermal Isometric Tension test, and wherein the bioprosthetic tissue has been prepared from a human tissue having an epidermal cellular layer with an underlying basement membrane matrix such that the human tissue's epidermal cellular layer has been removed, leaving the underlying basement membrane matrix intact in the bioprosthetic tissue.
US Pat. No. 11,027,049

DEVICES AND METHODS FOR DELIVERY OF BIOACTIVE AGENTS

Surmodics, Inc., Eden Pr...

1. A bioactive agent delivery device comprising:an expandable substrate forming part of a balloon;
a hydrophilic polymer layer disposed over the substrate, the hydrophilic polymer layer comprising a hydrophilic polymer comprising poly(ethylene glycol); and
a hydrophobic bioactive agent composition layer disposed over the surface of the hydrophilic polymer layer, the hydrophobic bioactive composition layer comprising one or more forms of paclitaxel; and
wherein the hydrophobic bioactive agent composition layer lacks the hydrophilic polymer.
US Pat. No. 11,026,794

REINFORCED BONE SCAFFOLD

Marquette University, Mi...

1. A scaffold for use in bone tissue engineering, the scaffold comprising:a skeleton constructed to form a three-dimensional shape defining a space, the skeleton constructed of a first material and having a first rate of biodegradation; and
a host component filling the space defined by the three-dimensional shape formed by the skeleton, the host component constructed of a second material and having a second rate of biodegradation, wherein the first rate of biodegradation is slower than the second rate of biodegradation;
wherein the skeleton and the host component form a unitary structure constructed throughout as an integrated body.
US Pat. No. 11,028,333

LUBRICATING OIL ADDITIVES

Infineum International Li...

1. A crankcase lubricating oil composition comprising:a major amount of an oil of lubricating viscosity; and
a minor amount of a metal-containing detergent, in the form of a concentrate in oil as a dispersion or a solution, comprising a gemini surfactant system derived from a C8-C30 double bond-unsaturated carboxylic acid, which double bond has been functionalized to form at least one polar group and which carboxylic acid has been functionalized to form an amide or ester group having at least one C4-C20 alkyl group.
US Pat. No. 11,028,078

ITRACONAZOLE ANALOGS AND USE THEREOF

The Johns Hopkins Univers...


US Pat. No. 11,028,335

GREASE COMPOSITION, METHOD FOR MANUFACTURING GREASE COMPOSITION, AND METHOD FOR USING GREASE COMPOSITION

IDEMITSU KOSAN CO., LTD.,...

1. A grease composition comprising:a base oil (A),
a thickener (B), and
a fire retardant (C),
wherein
the base oil (A) comprises a base oil (A1) having a 40° C. kinematic viscosity of 300 mm2/s or more, a sulfur content of 20 ppm by mass or less, and an initial boiling point of 400° C. or higher,
the fire retardant (C) comprises aluminum hydroxide (C1), 1,3,5-triazine-1,3,5 (2H, 4H, 6H)-tris(ethanol) (C2), or a combination thereof,
a content of the fire retardant (C) is from 1.0 to 12.0 mass % based on a total amount of the grease composition, and
a water content of the grease composition is less than 1.0 mass % based on the total amount of the grease composition.
US Pat. No. 11,029,618

CARRIER, ELECTROPHOTOGRAPHIC DEVELOPER AND PRODUCTION METHOD OF CARRIER

POWDERTECH CO., LTD., Ka...

1. A carrier comprising:(i) a magnetic core material having a surface; and
(ii) a resin coat layer coating the core material surface, wherein the resin coat layer comprises a mixture of:
(a) an elemental fluorine-containing resin;
(b) a polyimide (PI) resin having an imide bond in the main chain; and
(c) a surfactant;
wherein:
the surfactant has an elution amount of from 180 ppm to 3,500 ppm, remaining in water in an elution test comprising mixing the carrier into the water, filtering the carrier from the water, and measuring a weight of eluted material remaining after being removed from the water and dried, and
a mass ratio of the polyimide (PI) resin to the elemental fluorine-containing resin in the resin coat layer of 1/10 or more.
US Pat. No. 11,028,340

COMPOSITION FOR SURFACE TREATMENT, METHOD FOR PRODUCING THE SAME, SURFACE TREATMENT METHOD USING COMPOSITION FOR SURFACE TREATMENT, AND METHOD FOR PRODUCING SEMICONDUCTOR SUBSTRATE

FUJIMI INCORPORATED, Kiy...

1. A composition for surface treatment comprising:a polymer compound having at least one ionic functional group selected from the group consisting of a sulfonic acid (salt) group, a phosphoric acid (salt) group, and a phosphonic acid (salt) group; and
water, wherein;
when the ionic functional group is the sulfonic acid salt group, the sulfonic acid salt group is at least one selected from the group consisting of a sulfonic acid alkali metal salt and a sulfonic acid salt of a group bold 2 element;
when the ionic functional group is the phosphoric acid salt group, the phosphoric acid salt group is a phosphoric acid metal salt; and
when the ionic functional group is the phosphonic acid salt group, the phosphonic acid salt group is at least one selected from the group consisting of a phosphonic acid alkali metal salt and a phosphonic acid salt of a group 2 element,
a pH of the composition is less than 7, and
the polymer compound has a pKa of 3 or less and an ionic functional group density of more than 10%, wherein the ionic functional group density is represented by the following formula (1):
Ionic functional group density (%)=100×(Number of constituent unit derived from monomer having ionic functional group/Number of constituent unit derived from all monomers constituting polymer compound)  Formula (1).
US Pat. No. 11,028,343

CLEANING AGENT COMPOSITION FOR SUBSTRATE FOR SEMICONDUCTOR DEVICE

KAO CORPORATION, Tokyo (...

1. A cleaning agent composition for a substrate for a semiconductor device, the cleaning agent composition containing a component A, a component B, a component C, and a component D,the component A being sulfuric acid;
the component B being ascorbic acid;
the component C being at least one of thiourea and dithiothreitol; and
the component D being water.
US Pat. No. 11,027,577

TIRE

BRIDGESTONE CORPORATION, ...

1. A tire comprising:an attachment body to be attached to an axle;
a ring member including an inner cylinder externally covering the attachment body and an outer cylinder surrounding the inner cylinder from a tire radial outer side;
a plurality of connecting members arranged along a tire circumferential direction between the inner cylinder and the outer cylinder and connecting the inner cylinder and the outer cylinder to each other; and
a tread member made of vulcanized rubber and located on the tire radial outer side of the outer cylinder of the ring member;
wherein the tire is a non-pneumatic tire,
the ring member and the connecting members form a framework member and are made of a resin material;
wherein the resin material is made of a resin composition including 60 mass % or more of a polyamide resin formed by polymerizing an aliphatic diamine having 6 to 20 carbon atoms and an aliphatic dicarboxylic acid having 10 to 20 carbon atoms, and 40 mass % or less of a flexible component having a glass transition temperature of 0° C. or lower,
the flexible component includes poly ?-olefin, and
maleic anhydride is copolymerized with or grafted onto at least a portion of the poly ?-olefin.
US Pat. No. 11,028,346

DETERGENT COMPOSITION COMPRISING PROTEASE AND AMYLASE VARIANTS

1. A detergent composition comprising:(i) at least one alpha amylase variant comprising modifications to amino acid positions corresponding to amino acid positions selected from the group consisting of:
H1*+N54S+V56T+G109A+Q169E+Q172K+A174*+G182*+D183*+N195F+V206L+K391A+G476K;
H1*+N54S+V56T+G109A+R116H+A174S+G182*+D183*+N195F+V206L+K391A+G476K;
H1*+N54S+V56T+K72R+G109A+F113Q+R116Q+W167F+Q172G+A174S+G182*+D183*+G 18 4T+N195F+V206L+K391A+P473R+G476K;
H1*+N54S+V56T+G109A+F113Q+R116Q+Q172N+A174S+G182*+D183*+N195F+V206L+A26 5G+K391A+P473R+G476K;
H1*+N54S+V56T+K72 R+G 109A+F113Q+W167F+Q172R+A174S+G182*+D183*+N195F+V206L+K391A+G476K;
H1*+N54S+V56T+K72R+G109A+R116H+T134E+W167F+Q172G+L173V+A174S+G182*+D183*+N195F+V206L+G255A+K391A+G476K;
H1*+N54S+V56T+K72R+G109A+R116H+T134E+W167F+Q172G+L173V+A174S+G18 2*+D183*+N195F+V206L+G255A+K391A+Q395P+T444Q+P473R+G476K;
H1*+N54S+V56T+G109A+T134E+A174S+G182*+D183*+N195F+V206L+K391A+G476 K;
H1*+N54S+V56T+K72R+G109A+A174S+G182*+D183*+N195F+V206L+G255A+K391A+G476K; and
H1*+N54S+V56T+G109A+W167F+Q172E+L173P+A174K+G182*+D183*+N195F+V206L+K391A+G476K of the amino acid sequence of SEQ ID NO: 1,
wherein said alpha-amylase variant shares at least 85%, but less than 100% sequence identity with the amino acid sequence of SEQ ID NO: 1, and wherein said alpha-amylase variant has alpha-amylase activity; and
(ii) at least one protease having protease activity, wherein said protease is selected from the group consisting of:
(a) a protease having at least 85% sequence identity to the amino acid sequences of SEQ ID NOs: 2, 3, 19, 20, or 23;
(b) a protease variant comprising a substitution at one or more amino acid positions corresponding to amino acid positions 171, 173, 175, 179, or 180 of the amino acid sequence of SEQ ID NO: 2, wherein said protease variant has at least 85% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO: 2;
(c) a protease variant comprising a modification in one or more amino acid positions corresponding to amino acid positions 32, 33, 48, 49, 50, 51, 52, 53, 54, 58, 59, 60, 61, 62, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 116, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 150, 152, 153, 154, 155, 156, 158, 159, 160, 161, 164, 169, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 197, 198, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, or 216 of the amino acid sequence of SEQ ID NO: 3,
(d) a protease variant comprising a substitution in one or more amino acid positions corresponding to amino acid positions 9, 15, 27, 42, 52, 55, 56, 59, 60, 66, 74, 85, 97, 99, 101, 102, 104, 116, 118, 154, 156, 157, 158, 161, 164, 176, 179, 182, 185, 188, 198, 199, 200, 203, 206, 210, 211, 212, 216, 230, 232, 239, 242, 250, 253, 255, 256, or 269, of the amino acid sequence of SEQ ID NO: 3, wherein said protease variant has at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 3, and
(e) a protease variant comprising a substitution in one or more amino acid positions corresponding to amino acid positions 32, 33, 49, 50, 51, 52, 53, 54, 55, 60, 61, 62, 63, 64, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 118, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 152, 154, 155, 156, 157, 158, 161, 162, 163, 167, 170, 175, 181, 187, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 203, 204, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, or 222 of the amino acid sequence of SEQ ID NO: 23,
wherein said protease variant has at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 23.
US Pat. No. 11,028,347

STABLE UNIT DOSE DETERGENT PACS

1. A unit dose pac comprising:a container formed from a water-soluble or water-dispersible film; and
a liquid composition entrapped in the container, wherein the liquid composition is free of glycerin, propylene glycol and polyethylene glycol having a weight average molecular weight of about 400 g/mol and comprises:
(a) a beneficial composition comprising a C12-C14 alkyl ethoxylated sulphate in an amount of from about 8% to about 20% actives by weight of the liquid composition, and a C12-C15 alcohol ethoxylate in an amount of from about 20% to about 25% by weight of the liquid composition; and
(b) a solvent system comprising water in an amount of 24 to 25% by weight of the liquid composition, a single non-aqueous solvent selected from the group consisting of polyethylene glycol having a weight average molecular weight of about 3350 g/mol and polyethylene glycol 100 stearate and present in an amount of 25% by weight of the liquid composition, and a residual solvent comprising ethanol in an amount of from 0 to 5% by weight of the liquid composition.
US Pat. No. 11,028,348

NATURALLY-DERIVED ANTIMICROBIAL CLEANING SOLUTIONS

ProNatural Brands, LLC, ...

1. A method of chemically ablating biofilm, comprising contacting the biofilm with a mixture comprising a cleaning and disinfecting composition concentrate and water, wherein:the cleaning and disinfecting composition concentrate comprises an organic acid, a fatty acid, a surfactant, an alcohol, and water;
the organic acid is selected from one or more of citric acid, acetic acid, ascorbic acid, fumaric acid, propionic acid, oxalic acid, lactic acid, malic acid, and benzoic acid;
the cleaning and disinfecting composition concentrate comprises the organic acid at a concentration of 15% to about 35% (w/v);
the fatty acid is selected from one or more saturated or unsaturated C6-C18 monocarboxylic acids;
the cleaning and disinfecting composition concentrate comprises the fatty acid at a concentration of about 1% to about 3% (w/v);
the surfactant is a lauryl sulfate;
the cleaning and disinfecting composition concentrate comprises the surfactant at a concentration of about 3% to about 35% (w/v);
the alcohol is selected from ethanol, isopropanol, and n-propanol;
the cleaning and disinfecting composition concentrate comprises the alcohol at a concentration of about 2% to about 10% (w/v);
the cleaning and disinfecting composition concentrate is essentially free of halogenated molecules;
the cleaning and disinfecting composition concentrate is essentially free of oxidizing agents other than hydrogen peroxide;
the pH of the cleaning and disinfecting composition concentrate is less than 6.0;
the mixture comprises the cleaning and disinfecting composition concentrate and water at a ratio of about 1:10 to about 1:128; and
the biofilm is a biofilm of at least one organism selected from the group consisting of Pseudomonas aeruginosa, Escherichia coli, Listeria monocytogenes, Streptococcus, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Salmonella enterica, Dekkera bruxellensis, Vancomycin Resistant Enterococcus faecalis (VRE), Clostridium difficile, Legionella pneumophilia, Stenotrophomonas maltophilia, Carbapenem-Resistant Enterobacter cloacae (CRE), Enterobacter aerogenes, Neisseria gonorrhoeae, and Candida albicans.
US Pat. No. 11,027,325

HOT-FORMED METAL SHEET AND METHOD OF PRODUCING AN OPENING IN SUCH A METAL SHEET

Benteler Automobiltechnik...

1. A method, comprising:hot forming and press hardening a metal sheet in a press-hardening tool to a tensile strength of Rm >1300 megapascal (MPa); and
producing an opening with closed cutting line in the hot formed and press hardened metal sheet at the tensile strength Rm solely by high-speed punching the metal sheet in a single-step process with a punch at a speed of the punch of more than 6 m/s, sufficient to cause a momentary temperature rise in immediate proximity of the opening to at least minimize strain hardening and wherein the producing step is performed without the use of a counter holder.
US Pat. No. 11,028,349

CLEANSING COMPOSITIONS COMPRISING A MIXTURE OF PHENOL DISINFECTANTS

Colgate-Palmolive Company...

1. A personal care composition comprising:a) an antibacterial component comprising:
i) chloroxylenol present in an amount of 0.01% to 2% by weight of the composition; and
ii) o-cymen-5-ol present in an amount of 0.001% to 5% by weight of the composition;
b) an effective amount of a surfactant system comprising:
i) one or more fatty acid soaps;
ii) an anionic surfactant; and
iii) a betaine surfactant; and
c) an effective amount of a chelating agent,
wherein the composition has a pH of from 8-14, and the antibacterial component is free of Triclocarban, chlorinated compounds, Rhodasurf B7-B9, and Promidium CO.
US Pat. No. 11,028,094

PREPARATIVE SCALE CONVERSION OF GONYAUTOXINS TO NEOSAXITOXIN

1. A method of preparing a quantity of purified neoSTX comprising:(a) contacting in solution at a pH in the range 7.2 to 7.8 a quantity of GTX1,4 and a quantity of a dithiol at a temperature and for a time sufficient to provide a conversion product in which greater than 97.5% (w/w) of the quantity of GTX1,4 has been converted to neoSTX; and then
(b) applying the conversion product to a weak cation exchange sorbent and eluting with an aqueous weak acid to separate neoSTX from the dithiol and provide the quantity of purified neoSTX.
US Pat. No. 11,028,350

POWDERS AND GRANULES AND PROCESS FOR MAKING SUCH POWDERS AND GRANULES

BASF SE, Ludwigshafen am...

1. A process for making a powder or granule comprising at least one chelating agent selected from the group consisting of an alkali metal salt of methyl glycine diacetic acid (MGDA), an alkali metal salt of glutamic acid diacetate (GLDA), and an alkali metal salt of iminodisuccinic acid (IDS), wherein the alkali metal salt has a formula selected from the group consisting of formula (I a), (I b) and (I c):[CH3—CH(COO)—N(CH2—COO)2]M3-xHx  (I a)
wherein in formula (I a), M is, independently at each occurrence, an alkali metal cation, and x is from zero to 1.0,
[OOC—CH2CH2C—CH(COO)—N(CH2—COO)2]M4-xHx  (I b)
wherein in formula (I b), M is, independently at each occurrence, an alkali metal cation, and x is from zero to 2.0,
[H—N—(CH(COO)—CH2COO)2]M4-xHx  (I c)
wherein in formula (I c), M is, independently at each occurrence, an alkali metal cation, and x is from zero to 2.0,
the process comprising:
(a) introducing an aqueous solution or aqueous slurry of the chelating agent into a spray-dryer or spray-granulator, and removing most of the water by spray-drying or spray granulation using a gas with an inlet temperature of 125 to 250° C.,
(b) withdrawing powder or granules, from the spray-dryer or spray-granulator,
(c) separating off fines from the powder or granules, wherein the fines have a maximum particle diameter of 30 ?m in the case of powders and a maximum particle diameter of 350 ?m in the case of granules,
(d) separating off lumps from the powder or granules, wherein the lumps have a particle diameter of 250 ?m in the case of powders and 1,000 ?m or more in the case of granules, respectively,
(e) milling the lumps to a maximum particle diameter of 500 ?m in the case of granules or to 40 ?m in the case of powders, and
(f) re-introducing the fines from (c) and milled lumps from (e) into the spray-dryer or spray-granulator,
wherein the amount of fines is in a range of from 4 to 18% by total weight of the chelating agent withdrawn in (b), and the amount of milled lumps from (e) is in a range of from 20 to 40% by total weight of the chelating agent withdrawn in (b).
US Pat. No. 11,027,072

EMERGENCY DEVICES

Adamis Pharmaceuticals Co...

1. A high dose naloxone composition including naloxone at a dose greater than or equal to about 5 mg configured for administration, wherein Cmax is between 15 ng/mL to 24 ng/mL and the administration is an injection.
US Pat. No. 11,028,352

DETERGENT POUCH WITH ENZYMATIC WATER-SOLUBLE FILM

MONOSOL LLC, Merrilville...

1. A detergent pouch comprising a compartment formed by an enzyme containing water-soluble film, and a detergent containing a builder with a Ca2+ logarithmic stability constant of above 4.5.
US Pat. No. 11,028,358

CELL CULTURE LASER PHOTOABLATION

Synthego Corporation, Me...

1. A method comprising:a) selecting a cell based on its position on one or more surfaces or in one or more containers, wherein the selecting is not based on whether the cell comprises an exogenous label or an expressed reporter and wherein the selecting is performed using an imaging technique and an automated image analysis process; and
b) photoablating at least 80% of five or more cells on each of the one or more surfaces or in each of the one or more containers, wherein at least 95% of the one or more surfaces or containers contain only one viable cell after the photoablating is performed, wherein the cell selected in (a) is not photoablated.
US Pat. No. 11,028,361

COMPOSITIONS AND METHODS FOR STABILIZING SUSCEPTIBLE COMPOUNDS

Life Technologies Corpora...

1. A method of encapsulating a labile compound for protection from adverse reactions within a composition, comprising:a. reacting the labile compound with a dendrimer to produce a dendrimer-labile compound complex;
b. encapsulating the dendrimer-labile compound complex of step a) within a sequestering agent, to produce an encapsulated dendrimer-labile compound complex, and;
c. admixing the encapsulated dendrimer-labile compound complex of step b) with one or more components in the composition, wherein said labile compound is ethanolamine.
US Pat. No. 11,028,106

METHOD FOR PRODUCING TETRAALKOXYSILANE

NATIONAL INSTITUTE OF ADV...

1. A method for producing a tetraalkoxysilane, the method comprising:a first step of reacting an alcohol with a silicon oxide; and
a second step of bringing a vaporized component of the reaction mixture obtained in the first step into contact with a molecular sieve;
wherein:
the first step is carried out in a reactor whose temperature (T1) is controlled within the range of 200° C. the second step is carried out in a container whose temperature (T3) is controlled within the range of 10° C.?T3?150° C., and which includes the molecular sieve provided therein;
the vaporized component moves from the reactor to the container through an outward flow path whose temperature (T2) is controlled within the range of 190° C.?T2?300° C.; and
a component which has been brought into contact with the molecular sieve in the second step moves from the container to the reactor through an inward flow path.
US Pat. No. 11,028,362

DECELLULARIZED HUMAN AMNIOTIC MEMBRANE FOR CELL DELIVERY, CELL CULTURE AND INFLAMMATION PREVENTION

THE REGENTS OF THE UNIVER...

1. A hydrogel composition comprising:a powdered and freeze dried decellularized amniotic membrane (DCM), the amniotic membrane being decellularized using a method comprising:
adding to the amniotic membrane about a 3% detergent solution comprising t-octylphenoxypolyethoxyethanol solution to lyse the cells,
rinsing with de-ionized water to remove the detergent solution,
adding about a 4% sodium deoxycholic acid solution to further decellularize the membrane,
rinsing with de-ionized water to remove the acid solution,
adding a solution of about 0.1% peracetic acid/4% ethanol solution to remove residual nucleic acids,
rinsing with a composition comprising phosphate buffered saline and subsequently de-ionized water, and
removing excess water;
stem cells;
a non-cytotoxic cross-linking agent; and
a carrier comprising buffered saline.
US Pat. No. 11,028,107

STABLE SILYLATING REAGENTS

California Institute of T...

1. A solution composition prepared by preconditioning a mixture of:(a) a precursor hydrosilane; and
(b) a base comprising potassium hydroxide, a potassium alkoxide, a potassium silanolate, rubidium hydroxide, a rubidium alkoxide, a rubidium silanolate, cesium hydroxide, a cesium alkoxide, a cesium silanolate, a potassium amide, or a combination thereof; in
(c) a preconditioning solvent comprising one or more tetrahydrofurans, wherein the preconditioning solvent comprises 2-methyl-tetrahydrofuran;
in the absence of any heteroaromatic, olefinic, or acetylenic substrates capable of C—H silylation, or any alcohol substrates; wherein
the solution composition contains a species formed by the preconditioning of the mixture of (a) and (b) in the preconditioning solvent, wherein the species is present in sufficient amount to exhibit an observable infrared absorption peak in an Si—H stretching region of an infrared spectrum, that infrared absorption peak being of lower energy than a corresponding Si—H absorption peak of the precursor hydrosilane, when evaluated under comparable conditions; and wherein
(i) the solution composition comprises the preconditioning solvent comprising one or more tetrahydrofurans, wherein the preconditioning solvent comprises 2-methyl-tetrahydrofuran, and is free of any added heteroaromatic, olefinic, or acetylenic substrates capable of C—H silylation by the pre-conditioned mixture, or of any added alcohol substrates;
(ii) the preconditioning comprises holding the mixture of combined hydrosilane and the base in the preconditioning solvent under conditions sufficient to produce the solution composition, which is capable of initiating measurable silylation of 1-methyl indole at a temperature of 45° C. or less with an induction period of less than 30 minutes;
(iii) the precursor hydrosilane is of the Formula (I) or Formula (II):
(R)3?mSi(H)m+1   (I)
(R)3?m(H)mSi—Si(R)2?m(H)m+1   (II)where: m is independently 0, 1, or 2; and each R is independently optionally substituted C1-24 alkyl, optionally substituted C2-24 alkenyl, optionally substituted C2-24 alkynyl, optionally substituted C6-12 aryl, C3-12 heteroaryl, optionally substituted C7-13 alkaryl, optionally substituted C4-12 heteroalkaryl, optionally substituted C7-13 aralkyl, optionally substituted C4-12 heteroaralkyl, and, if substituted, the substituents are independently nitro, C1-C20 alkoxy, C5-C20 aryloxy, or halogen.
US Pat. No. 11,028,363

SUBPOPULATIONS OF SPORE-LIKE CELLS AND USES THEREOF

VCELL THERAPEUTICS, INC.,...

1. A composition comprising a sub-population of spore-like cells obtained from an initial population of spore-like cells isolated from a post-natal animal tissue or fluid containing cells, wherein the initial population of spore-like cells remain viable following oxygen deprivation for at least four hours,wherein the subpopulation of spore-like cells express one or more markers selected from the group consisting of: octamer-binding transcription factor 4 (Oct4), zinc finger protein 296 (Zfp296), cryptic family protein 1B (cripto), growth differentiation factor-3 (Gdf3), undifferentiated embryonic cell transcription factor 1 (UtF1), embryonic stem cell associated transcript 1 (Ecat1), embryonic stem cell-specific gene 1 (Esg1), sex determining region Y-box 2 (Sox2), paired box protein 6 (Pax6), stem cell antigen 1 (SCA-1), cluster of differentiation protein 29 (CD29), cluster of differentiation protein 34 (CD34), cluster of differentiation protein 90 (CD90), B1 integrin, tyrosine-protein kinase (cKit), surfactant protein C (SP-C), Clara cell 10 protein (CC10), splicing factor 1 (SF1), dosage-sensitive sex reversal gene 1 (DAX1), and superior cervical ganglion-10 protein (SCG10); and optionally,
wherein the composition is in a physiologically acceptable carrier.
US Pat. No. 11,028,364

COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE

President and Fellows of ...

1. A composition comprising T follicular regulatory (TFR) cells and a cytokine, wherein said composition has reduced immune suppressive activity,wherein the reduced immune suppressive activity results in a protective antibody response, and
wherein the cytokine is IL-21 or IL-6.
US Pat. No. 11,028,365

METHOD OF PRODUCING NATURAL KILLER CELLS AND COMPOSITION FOR TREATING CANCER

NKMAX Co., Ltd., Gyeongg...

1. A cell therapeutic composition, comprising:a therapeutically effective amount of at least one of CD56+ and/or CD3?/CD56+ NK cells, wherein purity of the NK cells in the cell therapeutic composition is at least 90% relative to other cells in the cell therapeutic composition;
IL-2 at a concentration of 50-50,000 IU/mL; and
a pharmaceutically acceptable carrier,
wherein the cell therapeutic composition is in a form suitable for administration to a human patient in need of NK cell therapy.
US Pat. No. 11,028,366

METHODS OF DIFFERENTIATING STEM CELLS BY MODULATING MIR-124

Accelerated BioSciences C...

1. A method for increasing insulin production in a human in need thereof, comprising administering an isolated human pancreatic progenitor cell to the human in need thereof, wherein the isolated human pancreatic progenitor cell expresses insulin and betatrophin, whereby the insulin production in the human is increased in response to glucose stimulation in the human.
US Pat. No. 11,028,367

EPITHELIAL CELL DIFFERENTIATION OF HUMAN MESENCHYMAL STROMAL CELLS

YALE UNIVERSITY, New Hav...

1. A method of differentiating an adipose tissue-derived mesenchymal stem cell (AT-MSC) into a lung cell, the method comprising:seeding the AT-MSC on an ex vivo substrate; and
exposing the AT-MSC seeded substrate to small airway growth medium that comprises at least one of retinoic acid and human epidermal growth factor, thereby differentiating the AT-MSC into a lung cell that expresses at least one epithelial marker, wherein the lung cell exhibits at least one characteristic of a Clara cell, wherein the at least one characteristic of a Clara cell comprises expression of Clara cell secretory protein (CCSP).
US Pat. No. 11,028,368

SYSTEM AND SUBSTANCES FOR CRYOPRESERVATION OF VIABLE CELLS

Membrane Protective Techn...

1. A process to enhance the cryopreservation of biological cells comprising the steps of:assembling a cellular collection containing a plurality of biological cells;
establishing a lipid containing cryopreservation fluid to be later incorporated with said biological cells in cryopreservation;
after said step of establishing a lipid containing cryopreservation fluid to be later incorporated with said biological cells in cryopreservation, adding at least 270 j/kg surface energy to substantially all of said lipid in said lipid containing cryopreservation fluid without filtering said lipid containing cryopreservation fluid to create a lipid surface energy increased cryopreservation fluid by the multiplication in the number of discrete lipid droplets in the fluid without changing the total concentration (v/v or w/v) of the lipid relative to the remaining cryopreservation fluid components;
after said step of adding said at least 270 j/kg surface energy to substantially all of said lipid in said lipid containing cryopreservation fluid to create said lipid surface energy increased cryopreservation fluid, mixing substantially all of said lipid surface energy increased cryopreservation fluid and said biological cells to form an energy increased fluidic cryopreservation composite;
removing thermal energy from said fluidic cryopreservation composite;
freezing said fluidic cryopreservation composite by reducing the temperature of said fluidic cryopreservation composite below the freezing point of water; and
providing an enhanced post-cryogenic viability for said biological cells as a result from said above steps.
US Pat. No. 11,028,369

INDUCED EXTENDED PLURIPOTENT STEM CELLS, METHOD OF MAKING AND USING

Beihao Stem Cell and Rege...

1. A cell culture medium for extending cell potency of an isolated pluripotent stem cells, the cell culture medium comprising(i) 1-100 ng/ml of human leukemia inhibitory factor (LIF),
(ii) 0.5-5.0 ?M of 6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidin-yl]amino]ethyl]amino]-3-pyridinecarbonitrile,
(iii) 1.0-5.0 ?M of (S)-(+)-Dimethindene maleate (DiM), and
(iv) 0.5-5.0 ?M of Minocycline hydrochloride (MiH), wherein said culture medium maintains the normal karyotype and extend the pluripotent state of the pluripotent stem cells for at least 5 passages.
US Pat. No. 11,028,370

RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLS

1. A purified RNA preparation comprising in vitro-synthesized single-stranded mRNA molecules that:A) encode at least one iPSC induction factor selected from the group consisting of OCT4, SOX2, KLF4, LIN28, NANOG, and a MYC protein selected from c-MYC, L-MYC and N-MYC;
B) comprise (i) guanosine, (ii) adenosine, (iii) cytidine, (iv) pseudouridine (?) or 1-methyl-pseudouridine (m1?) in place of uridine, (v) a 5? cap, and (vi) a 3? poly(A) tail; and
C) have been purified using a purification process that removes RNA contaminant molecules that are immunogenic and toxic to mammalian cells by inducing an innate immune response, such that said mRNA molecules lack immunogenicity, as can be determined using an in vitro monocyte-derived dendritic cell (MDDC) immunogenicity assay by measuring an amount of IFN-? or TNF-? cytokine secreted from human or murine MDDCs transfected with said purified RNA preparation that is no greater than the amount of IFN-? or TNF-? secreted by MDDCs transfected with negative controls that do not contain RNA.
US Pat. No. 11,028,371

PERSONALIZED CELLS, TISSUES, AND ORGANS FOR TRANSPLANTATION FROM A HUMANIZED, BESPOKE, DESIGNATED-PATHOGEN FREE, (NON-HUMAN) DONOR AND METHODS AND PRODUCTS RELATING TO SAME

Xenotherapeutics, Inc., ...

1. A genetically reprogrammed, biologically active and metabolically active cell, tissue, and/or an organ comprising live cells that vascularize after xenotransplantation, wherein the genetically reprogrammed, biologically active and metabolically active cell, tissue, and/or an organ has been obtained from a non-wild type, biologically engineered swine comprising a nuclear genome that has been reprogrammed to replace a plurality of nucleotides in a plurality of exon regions of a major histocompatibility complex of a wild-type swine with a plurality of synthesized nucleotides from a human captured reference sequence, andwherein cells of said genetically reprogrammed swine do not present one or more surface glycan epitopes selected from alpha-Gal, Neu5Gc, and SDa,
wherein genes encoding alpha-1,3 galactosyltransferase, cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH), and ?1,4-N-acetylgalactosaminyltransferase are altered such that the genetically reprogrammed swine lacks functional expression of surface glycan epitopes encoded by said genes,
wherein the reprogrammed genome comprises site-directed mutagenic substitutions of nucleotides at exon regions of: i) at least one of the wild-type swine's SLA-1, SLA-2, and SLA-3 with nucleotides from an orthologous exon region of HLA-A, HLA-B, and HLA-C, respectively, of the human captured reference sequence; and ii) at least one the wild-type swine's SLA-6, SLA-7, and SLA-8 with nucleotides from an orthologous exon region of HLA-E, HLA-F, and HLA-G, respectively, of the human captured reference sequence; and iii) at least one of the wild-type swine's SLA-DR and SLA-DQ with nucleotides from an orthologous exon region of HLA-DR and HLA-DQ, respectively, of the human captured reference sequence,
wherein intron regions of the wild-type swine's genome are not reprogrammed, and
wherein the reprogrammed genome comprises at least one of A-C:
A) wherein the reprogrammed swine nuclear genome comprises site-directed mutagenic substitutions of nucleotides at exon regions of the wild-type swine's ?2-microglobulin with nucleotides from orthologous exons of a known human ?2-microglobulin from the human captured reference sequence;
B) wherein the reprogrammed swine nuclear genome comprises a polynucleotide that encodes a polypeptide that is a humanized beta 2 microglobulin (hB2M) polypeptide sequence that is at least 95% identical to the amino acid sequence of beta 2 microglobulin glycoprotein expressed by the human captured reference genome;
C) wherein the reprogrammed swine nuclear genome has been reprogrammed such that, at the swine's endogenous ?2-microglobulin locus, the nuclear genome has been reprogrammed to comprise a nucleotide sequence encoding ?2-microglobulin polypeptide of the human recipient,
wherein the reprogrammed swine nuclear genome has been reprogrammed such that the genetically reprogrammed swine lacks functional expression of the wild-type swine's endogenous ?2-microglobulin polypeptides,
wherein said reprogramming does not introduce any frameshifts or frame disruptions,
wherein said genetically reprogrammed swine is free of at least the following pathogens:
(i) Ascaris species, Cryptosporidium species, Echinococcus, Strongyloids sterocolis, and Toxoplasma gondii in fecal matter;
(ii) Leptospira species, Mycoplasma hyopneumoniae, porcine reproductive and respiratory syndrome virus (PRRSV), pseudorabies, transmissible gastroenteritis virus (TGE)/Porcine Respiratory Coronavirus, and Toxoplasma gondii by determining antibody titers;
(iii) Porcine Influenza;
(iv) the following bacterial pathogens as determined by bacterial culture: Bordetella bronchisceptica, Coagulase-positive staphylococci, Coagulase-negative staphylococci, Livestock-associated methicillin resistant Staphylococcus aureus (LA MRSA), Microphyton and Trichophyton spp.;
(v) Porcine cytomegalovirus; and
(vi) Brucella suis, and
wherein said genetically reprogrammed swine is maintained according to a bioburden-reducing procedure, said procedure comprising maintaining the swine in an isolated closed herd, wherein all other animals in the isolated closed herd are confirmed to be free of said pathogens, and wherein the swine is isolated from contact with any non-human animals and animal housing facilities outside of the isolated closed herd.
US Pat. No. 11,028,373

ENGINEERED GLUCOSYLTRANSFERASES

1. A non-native glucosyltransferase comprising an amino acid substitution at a position corresponding with amino acid residue Phe-607 of SEQ ID NO:62,wherein the non-native glucosyltransferase synthesizes alpha-glucan comprising 1,3-linkages, and
wherein the non-native glucosyltransferase has:
(i) an alpha-glucan yield that is higher than the alpha-glucan yield of a second glucosyltransferase that only differs from the non-native glucosyltransferase at the substitution position(s) position, and/or
(ii) a leucrose yield that is lower than the leucrose yield of the second glucosyltransferase;
wherein the non-native glucosyltransferase comprises a catalytic domain that is at least about 90% identical to residues 55-960 of SEQ ID NO:4, residues 54-957 of SEQ ID NO:65, residues 55-960 of SEQ ID NO:30, residues 55-960 of SEQ ID NO:28, or residues 55-960 of SEQ ID NO:20.
US Pat. No. 11,028,374

METHODS FOR TREATING ANEMIA IN A SUBJECT IN NEED THEREOF

ACCELERON PHARMA INC., C...

1. A method of treating anemia in a subject in need thereof, comprising subcutaneously administering to the subject a polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1, wherein the polypeptide comprises an acidic amino acid at the position corresponding to position 79 of SEQ ID NO: 1, wherein the polypeptide binds to GDF11 and/or myostatin.
US Pat. No. 11,028,375

METHODS FOR TREATING ANEMIA IN A SUBJECT IN NEED THEREOF

ACCELERON PHARMA INC., C...

1. A method of treating anemia in a subject in need thereof, the method comprising administering to the subject an aqueous formulation, wherein the aqueous formulation comprises a polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence of amino acids 29-109 of SEQ ID NO: 1, wherein the polypeptide comprises an acidic amino acid at the amino acid position corresponding to position 79 of SEQ ID NO: 1; wherein the polypeptide binds to GDF11 and/or myostatin; and wherein the formulation comprises Tris, a buffer, and/or a polyol.
US Pat. No. 11,028,376

DNA POLYMERASES FROM THE RED SEA BRINE POOL

KING ABDULLAH UNIVERSITY ...

1. A composition for amplifying nucleic acids comprising:an isolated DNA polymerase comprising the sequence of SEQ ID NO:3 and an amount of Ethylenediaminetetraacetic acid (EDTA), Tris-HCl and/or dithiothreitol (DTT).
US Pat. No. 11,028,121

MULTISIGNAL LABELING REAGENTS AND PROCESSES AND USES THEREFOR

ENZO LIFE SCIENCES, INC.,...

1. A multi-signal labeling reagent, comprising:a plurality of first nucleic acid strands covalently bound to the first member of a binding pair and not to the second member of the binding pair; and
a plurality of second nucleic acid strands covalently bound to a second member of the binding pair and not to the first member of the binding pair,
wherein at least some of the nucleic acid monomers of one or both of the first nucleic acid strands and the second nucleic acid strands comprise a covalently linked signal moiety, and
wherein the binding pair is not a nucleic acid binding pair.
US Pat. No. 11,028,377

PHYTASE VARIANTS YKAPPA HAVING IMPROVED PEPSIN RESISTANCE AND INCREASED CATALYTIC EFFICIENCY

FEED RESEARCH INSTITUTE C...

1. A Phytase YkAPPA variant having the amino acid sequence obtained by substituting glutamic acid at the 230th site of the sequence of SEQ ID NO:1 with glycine, proline, or arginine, and having improved pepsin resistance and increased catalytic efficiency.
US Pat. No. 11,028,378

PROCESS OF EXTRACTING OIL FROM THIN STILLAGE

1. A process of recovering oil, comprising(a) converting a starch-containing material into dextrins with an alpha-amylase;
(b) saccharifying the dextrins using a carbohydrate source generating enzyme to form a sugar;
(c) fermenting the sugar in a fermentation medium into a fermentation product using a fermenting organism;
(d) recovering the fermentation product to form a whole stillage;
(e) separating the whole stillage into thin stillage and wet cake;
(e?) optionally concentrating the thin stillage into syrup;
(f) recovering oil from the thin stillage and/or optionally the syrup, wherein a protease and a phospholipase are present and/or added during steps (a) to (c) wherein the protease present and/or added in steps (a) to (c) is a protease having the amino acid sequence set out in SEQ ID NO: 4 herein, or a protease which has at least 90% identity to SEQ ID NO: 4 having a protease activity, wherein the phospholipase present and/or added in steps (a) to (c) is: (i) the phospholipase shown in SEQ ID NO: 15 herein or one having a sequence identity thereto of at least 90% having a phospholipase activity; or (ii) the phospholipase shown in SEQ ID NO: 16 herein or one having a sequence identity thereto of at 90% having a phospholipase activity; or (iii) the phospholipase shown in SEQ ID NO: 17 herein or one having a sequence identity thereto of at least 90% having a phospholipase activity.
US Pat. No. 11,028,123

CAPPING OF UNPROTECTED AMINO GROUPS DURING PEPTIDE SYNTHESIS

SANOFI-AVENTIS DEUTSCHLAN...

1. A method for the solid-phase synthesis of lixisenatide SEQ ID NO:1), the method comprising coupling cycles of amino acid building blocks of lixisenatide to an amino acid chain,wherein said amino acid building blocks comprise an unprotected C-terminal carboxyl group and a protected N-terminal amino group comprising an Fmoc protecting group,
wherein said amino acid chain comprises an unprotected N-terminal amino group, and
wherein at least one coupling cycle comprises the steps:
(a) coupling the amino acid building block C-terminally at the unprotected N-terminal amino group of the amino acid chain, so that an amide bond is formed between the amino acid chain and the amino acid building block,
(b) contacting the product obtained in step (a) with a capping reagent comprising a capping compound, wherein the capping compound binds to an unprotected N-terminal amino group of the amino acid chain to which no building block has been coupled in step (a), and
(c) de-protecting the N-terminal amino group of the amino acid building block,
wherein the method comprises sufficient coupling cycles to produce lixisenatide (SEQ ID NO:1), and
wherein step (b) is performed after coupling of the amino acid building block at positions Arg(20), Glu(17), Gln(13, Leu(10) or Gly(4) of the lixisenatide sequence.
US Pat. No. 11,028,379

FCE MRNA CAPPING ENZYME COMPOSITIONS, METHODS AND KITS

New England Biolabs, Inc....

1. An FCE variant having (a) an amino acid sequence at least 90% identical to positions 1 to 878 of SEQ ID NO: 1, and (b) a substitution relative to SEQ ID NO: 1 at a position corresponding to positions 215, 337, 572, 648, or 833 of SEQ ID NO: 1.
US Pat. No. 11,028,380

CAS9-CAS9 FUSION PROTEINS

University of Massachuset...

1. A fusion protein comprising a first Cas9 nuclease, said first nuclease comprising a protospacer adjacent motif recognition domain having a lysine-substituted, alanine-substituted or serine-substituted arginine residue and a second Cas9 nuclease.
US Pat. No. 11,028,381

CRISPR-ASSOCIATED (CAS) PROTEIN

Locanabio, Inc., San Die...

1. A method of directing a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) nucleoprotein complex to a selected nucleic acid target sequence, the method comprising:contacting the selected nucleic acid target sequence with one or more nucleoprotein complexes comprising
a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) protein, wherein the Cas protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:44, an amino acid sequence having at least 98 percent sequence identity to SEQ ID NO:37, an amino acid sequence having at least 98 percent sequence identity to SEQ ID NO:39, and an amino acid sequence having at least 98 percent sequence identity to SEQ ID NO:44; and
a cognate nucleic acid guide comprising a repeat sequence and a spacer sequence, wherein the repeat sequence and the spacer sequence do not naturally occur together, wherein the Cas protein and the cognate nucleic acid guide form the nucleoprotein complex, and wherein the nucleoprotein complex binds to the selected nucleic acid target sequence.
US Pat. No. 11,032,224

RNA TARGETING METHODS AND COMPOSITIONS

Salk Institute for Biolog...

1. A method of targeting one or more target ribonucleic acid (RNA) molecules, comprising:contacting one or more target RNA molecules with a non-naturally occurring or engineered clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) system comprising:
at least one Cas13d protein comprising at least 95% sequence identity to SEQ ID NO: 42, or a nucleic acid molecule encoding the at least one Cas13d protein; and
at least one CRISPR-Cas system guide RNA (gRNA) comprising one or more direct repeat (DR) sequences and one or more spacer sequences, which hybridizes with the one or more target RNA molecules, or at least one nucleic acid molecule encoding the gRNA,
whereby the Cas13d protein forms a complex with the gRNA, wherein the gRNA directs the complex to the one or more target RNA molecules and targets the one or more target RNA molecules.